var title_f12_30_12768="Rectal exam PI";
var content_f12_30_12768=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F80412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F80412&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Rectal exam",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During a digital rectal exam, the doctor or nurse puts a finger inside your rectum and feels your prostate gland. That way he or she can see how big it is and whether it has bumps or dents or anything unusual.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12768=[""].join("\n");
var outline_f12_30_12768=null;
var title_f12_30_12769="Pomeroy tubal ligation D";
var content_f12_30_12769=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76868&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pomeroy tubal ligation D",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 449px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12769=[""].join("\n");
var outline_f12_30_12769=null;
var title_f12_30_12770="Circuitry of CAVHD";
var content_f12_30_12770=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F75680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F75680&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Schematic diagram showing circuitry for continuous arteriovenous hemodialysis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the circuitry required for the adequate performance of continuous arteriovenous hemodialysis (CAVHD). Dialysis fluid is infused into the hemofilter via a dialysate infusion pump. In this drawing, the dialysis outflow drains into the collection bag by gravity alone; if desired, the outflow rate may also be controlled via the infusion pump machine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Sigler, M, Teehan, B. In: Glassock, R (Ed), Current Therapy in Nephrology and Hypertension, Mosby, St. Louis, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12770=[""].join("\n");
var outline_f12_30_12770=null;
var title_f12_30_12771="Crossed renal ectopia";
var content_f12_30_12771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Crossed renal ectopia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Different forms of crossed renal ectopia. Fused: Ectopic kidney moves across the midline and fuses to the lower pole of the normally positioned contralateral kidney. Nonfused: Ectopic kidney moves across the midline without fusion and positioned at the rim of the pelvis (pelvic kidney). Bilateral: Both kidneys are ectopic and cross the midline with the ureters maintaining their normal bladder insertion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12771=[""].join("\n");
var outline_f12_30_12771=null;
var title_f12_30_12772="Group A streptococcal balanoposthitis";
var content_f12_30_12772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F61240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F61240&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Group A streptococcal balanoposthitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 300px; height: 519px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Erosion and purulent exudates of the foreskin and glans penis in Case 1. B) Erosion and purulent exudates of the foreskin and glans penis in Case 2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Sakuma, S, Komiya, H. Balanitis caused by Streptococcus pyogenes: a report of two cases. Int J STD AIDS. 2005 Sep; 16(9): 644-5, by permission of The Royal Society of Medicine Press, London. Copyright &copy;2005 Royal Society of Medicine Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12772=[""].join("\n");
var outline_f12_30_12772=null;
var title_f12_30_12773="Glucocorticoid gene suppression";
var content_f12_30_12773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70776&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Glucocorticoid suppression of activated inflammatory genes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 376px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inflammatory genes are activated by inflammatory stimuli, such as interleukin-1b (IL-1b) or tumor necrosis factor-a (TNF-a), resulting in activation of IKK2 (inhibitor of I-kB kinase-2), which activates the transcription factor nuclear factor kB (NF-kB). A dimer of p50 and p65 NF-kB proteins translocates to the nucleus and binds to specific kB recognition sites and also to coactivators, such as CREB-binding protein (CBP) or p300/CBP-activating factor (pCAF), which have intrinsic histone acetyltransferase (HAT) activity. This results in acetylation of core histone H4, resulting in increased expression of genes encoding multiple inflammatory proteins. Glucocorticoid receptors (GR) after activation by glucocorticoids translocate to the nucleus and bind to coactivators to inhibit HAT activity directly and recruiting histone deacetylase-2 (HDAC2), which reverses histone acetylation leading in suppression of these activated inflammatory genes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12773=[""].join("\n");
var outline_f12_30_12773=null;
var title_f12_30_12774="Overview on renal replacement therapy (RRT) for children with chronic kidney disease";
var content_f12_30_12774=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview on renal replacement therapy (RRT) for children with chronic kidney disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12774/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12774/contributors\">",
"     Lesley Rees, MD, FRCPCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12774/contributors\">",
"     Bradley A Warady, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12774/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12774/contributors\">",
"     Tej K Mattoo, MD, DCH, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12774/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12774/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/30/12774/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H118550482\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with chronic kidney disease (CKD), as the estimated glomerular filtration rate declines to less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (stage 4 CKD), preparations for renal replacement therapy (RRT) are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/1\">",
"     1",
"    </a>",
"    ]. The family and, if appropriate, the child should be provided with information related to preemptive kidney transplantation, peritoneal dialysis, and hemodialysis.",
"   </p>",
"   <p>",
"    The choice and timing of renal replacement therapy for children with CKD are reviewed here. Topic reviews that include more comprehensive descriptions of the different forms of RRT for pediatric CKD including complications and outcome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=see_link\">",
"     \"Hemodialysis for children with chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28153?source=see_link\">",
"     \"Chronic peritoneal dialysis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23543?source=see_link\">",
"     \"General principles of kidney transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22154?source=see_link\">",
"     \"Complications of renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118550572\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Classification schema for chronic kidney disease in children is based upon the level of kidney function (defined by glomerular filtration rate [GFR]) as follows (",
"    <a class=\"graphic graphic_table graphicRef80596 \" href=\"UTD.htm?22/4/22603\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage 1 disease &mdash; Normal GFR (&ge; 90",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2)",
"     </li>",
"     <li>",
"      Stage 2 disease &mdash; GFR between 60 and 89",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 3 disease &mdash; GFR between 30 and 59",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 4 disease &mdash; GFR between 15 and 29",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2",
"     </li>",
"     <li>",
"      Stage 5 disease &mdash; GFR of less than 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 or end-stage kidney disease (ESKD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    GFR increases with maturation from infancy and approaches adult mean values by two years of age. Children under two years of age do not fit within the above classification system because they normally have a low GFR even when corrected for body surface area. In these patients, calculated GFR based upon serum creatinine can be compared to normative age-appropriate values to detect kidney impairment.",
"   </p>",
"   <p>",
"    The GFR can be estimated by using the Schwartz formula, which is based upon serum creatinine, age, height, and in adolescents, the gender of the patient (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?23/40/24193?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    GFR = k X Height (cm)",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    Screat",
"   </p>",
"   <p>",
"    Height represents the body height measured in centimeters, and Screat is the serum creatinine in",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    The constant k is directly proportional to the muscle component of body, and varies with age. The estimated GFR also depends on the laboratory assay used to measure serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The value for k is 0.33 in premature infants through the first year of life, 0.45 for term infants through the first year of life, 0.55 in children and adolescent girls, and 0.7 in adolescent boys are used when serum creatinine is measured by Jaffe method.",
"     </li>",
"     <li>",
"      The value for k is 0.413 for all children with CKD between ages 1 and 16 years when the clinical laboratory reports serum creatinine normalized to isotope-dilution mass spectrometry (IDMS) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Definitions and classifications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=see_link&amp;anchor=H26#H26\">",
"     \"Clinical presentation and evaluation of chronic kidney disease in children\", section on 'Serum creatinine and GFR'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363124244\">",
"    <span class=\"h1\">",
"     INCIDENCE OF ESKD AND RRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;RRT is initiated in children with",
"    <strong>",
"    </strong>",
"    CKD stage 5, and in some children with late CKD stage 4. (See",
"    <a class=\"local\" href=\"#H118550707\">",
"     'Timing of RRT'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    ESKD (CKD stage 5) in children is uncommon. The highest estimated incidences for ESKD in children were reported in the United States and New Zealand with annual rates of 15.5 and 18 per million children, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The lowest annual incidence of ESKD was reported in Japan with a rate of 4 per million children at or below 19 years of age. &nbsp;",
"   </p>",
"   <p>",
"    The variability in the worldwide incidence of ESKD is thought to be affected by genetic and environmental factors, the ability to diagnosis and manage children with significant renal impairment, and the threshold of when RRT is initiated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/5\">",
"     5",
"    </a>",
"    ]. In particular, the developed countries are more likely to possess the necessary resources for the detection and treatment of ESKD.",
"   </p>",
"   <p>",
"    In the United States, the incidence of starting RRT for pediatric ESKD is about 15 patients per million population of children, which represented 1304 new patients in 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/6\">",
"     6",
"    </a>",
"    ]. This represents nearly a 6 percent annual increase since 2000. In the United Kingdom [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/7\">",
"     7",
"    </a>",
"    ], and Australia and New Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/8\">",
"     8",
"    </a>",
"    ], the numbers of children starting RRT have been stable with an incidence of new patients of 8 and 10 per million child population respectively. The overall prevalence of RRT has increased due to improved survival.",
"   </p>",
"   <p>",
"    Causes of ESKD in children are very different from those in adults. The most common cause of pediatric ESKD is congenital anomalies of the kidney and ureter (CAKUT), although the proportion of cases with CAKUT decreases with increasing age due to the increase incidence of acquired glomerular disease (",
"    <a class=\"graphic graphic_figure graphicRef68637 \" href=\"UTD.htm?40/1/40990\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"     \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363124528\">",
"    <span class=\"h1\">",
"     CHOICE OF RRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;RRT choices in children with CKD include renal transplantation, hemodialysis, and peritoneal dialysis. The choice of RRT varies as illustrated by the following findings from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) centers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/9\">",
"     9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      One quarter of children underwent preemptive renal transplantation",
"     </li>",
"     <li>",
"      One half were started on peritoneal dialysis (PD)",
"     </li>",
"     <li>",
"      One quarter were started on hemodialysis (HD)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although HD and PD are technically feasible in children of all ages, in general, transplantation is the ultimate aim for the majority of children with ESKD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445803611\">",
"    <span class=\"h2\">",
"     Preemptive renal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preemptive transplantation is the preferred RRT, which is performed prior to the need for dialysis, because [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Renal transplantation is associated with better outcomes in health related quality of life measures, growth, and development than either peritoneal dialysis or hemodialysis.",
"     </li>",
"     <li>",
"      Mortality is higher in patients undergoing chronic dialysis.",
"     </li>",
"     <li>",
"      Dialysis is more disruptive to family lifestyle, schooling, and social interactions.",
"     </li>",
"     <li>",
"      Avoidance of dialysis preserves vascular and peritoneal access sites for future use (ie, lifetime for a child), if the transplant should fail.",
"     </li>",
"     <li>",
"      Dietary and fluid restrictions are necessary on dialysis.",
"     </li>",
"     <li>",
"      As in adults, dialysis is associated with vascular calcification and the risk of cardiovascular events, which occur at a proportionately earlier age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"       \"Vascular calcification in chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preemptive transplantation is more easily accomplished in children than adults because of the availability of parental donors in many cases who are a haplotype match, are relatively young and healthy, and are frequently willing to donate a kidney. In addition, because pediatric nephrologists generally follow their patients from the early stages of CKD, they can more easily prepare the patient and their family for transplantation and avoid initiating dialysis. If a living related donor is not available, many countries prioritize children on the deceased donor transplant waiting list.",
"   </p>",
"   <p>",
"    Despite these advantages, preemptive transplantation is still not achieved in the majority of children with ESKD, because they may present in CKD stage 5 with insufficient preparatory time required for transplantation prior to the need for dialysis, have a prior transplant that is failing, or transplantation is not possible or advisable due to small size, comorbidity, non-adherence to medical therapy, family instability or other factors.",
"   </p>",
"   <p>",
"    In 2008, preemptive transplantation occurred in only 12 percent of European children [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/11\">",
"     11",
"    </a>",
"    ], and 16 percent of children in Australia and New Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/8\">",
"     8",
"    </a>",
"    ]. In North America, the rate is higher at 24 percent based on data from the North America Pediatric Renal Trails and Collaborative Studies registry from 1987 through 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H445803487\">",
"    <span class=\"h2\">",
"     Choice of dialysis modality",
"    </span>",
"    &nbsp;&mdash;&nbsp;When preemptive transplantation is not an option, the choice between the two forms of dialysis for ESKD is generally dictated by patient age, technical, social, and compliance issues, and family preference. The choice between the two modalities varies worldwide as there are no data that demonstrate significant differences in outcome between the two modalities, either in children or adults.",
"   </p>",
"   <p>",
"    HD is the initial RRT in 62, 50, and 40 percent of children with ESKD in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/11\">",
"     11",
"    </a>",
"    ], the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/6\">",
"     6",
"    </a>",
"    ], and Australia and New Zealand [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/8\">",
"     8",
"    </a>",
"    ], respectively. The choice of long term dialysis also varies. In the United States, the use of PD and HD remains similar [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/6\">",
"     6",
"    </a>",
"    ]. In Europe, there is an increasing predominance of PD over HD, with a ratio of approximately 2:1 for PD to HD, although this may vary within Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/11\">",
"     11",
"    </a>",
"    ]. In Japan and Turkey, PD is both the preferred initial and long-term modality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In general, the following factors are used to choose dialysis modality:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In infants and young children, PD is preferred because it is technically easier to perform than HD as it does not require a vascular access or venipuncture, and it allows for a more liberal fluid intake [",
"      <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/13,14\">",
"       13,14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=see_link\">",
"       \"Hemodialysis for children with chronic kidney disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28153?source=see_link&amp;anchor=H3926445#H3926445\">",
"       \"Chronic peritoneal dialysis in children\", section on 'Peritoneal dialysis versus hemodialysis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PD may be precluded in children with intra-abdominal pathology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28153?source=see_link&amp;anchor=H15616680#H15616680\">",
"       \"Chronic peritoneal dialysis in children\", section on 'Contraindications to CPD'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Home dialysis (PD or HD) may be precluded by social difficulties. In these families, choice is dictated by the dialytic modality available for children at a nearby center.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H118550707\">",
"    <span class=\"h1\">",
"     TIMING OF RRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in adults, some form of RRT is generally needed in children when the GFR falls below 15",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (stage 5 CKD). At that level of kidney function, the classical clinical indications for dialysis include fluid overload, uremic symptoms, and uncontrolled metabolic abnormalities (eg, hyperkalemia).",
"   </p>",
"   <p>",
"    RRT may be initiated earlier in children with CKD primarily to permit the provision of the nutritional needs necessary to maintain normal (or near normal) growth. As noted above, preemptive renal transplantation is the preferred modality as it is the intervention that provides the best outcomes regarding growth, development, quality of life, and patient survival. On the other hand, some children with continuing good urine volumes can be maintained off dialysis for a substantial period of time with very low GFRs if strict attention is paid to growth, nutrition, and therapeutic control of metabolic abnormalities. (See",
"    <a class=\"local\" href=\"#H445803611\">",
"     'Preemptive renal transplantation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who undergo dialysis as the initial RRT, earlier indications for intervention prior to stage 5 CKD may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children with nephrotic syndrome requiring bilateral nephrectomies pretransplant.",
"     </li>",
"     <li>",
"      Correction of metabolic abnormalities that fail medical management including hyperkalemia, hyperphosphatemia, and metabolic acidosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Hyperkalemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Metabolic acidosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inadequate nutrition because of fluid limitations. This is especially an issue with infants who are maintained on a completely liquid diet (ie, formula or breast milk). In these patients, dialysis is instituted to allow the required volume of feeds to maintain adequate growth.",
"     </li>",
"     <li>",
"      Hypertension that is refractory to dietary sodium restriction and medications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Planning for initiation of dialysis is dependent upon the chosen modality.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodialysis: Children who are to receive hemodialysis will need evaluation for vascular access. Vascular access options include arteriovenous (AV) fistula or a central venous tunneled catheter. AV fistulae require time to mature prior to use, which may be several weeks to months. As a result, if an AV fistula is chosen, it needs to be several weeks to months prior to the initiation of dialysis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=see_link\">",
"       \"Hemodialysis for children with chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Peritoneal dialysis: Children who are to initiate peritoneal dialysis need to undergo abdominal surgery for placement of a peritoneal dialysis catheter. Use of a double cuff catheter has been associated with fewer infectious complications of PD [",
"      <a class=\"abstract\" href=\"UTD.htm?12/30/12774/abstract/9\">",
"       9",
"      </a>",
"      ]. Ideally, there should be ample time for the abdominal wound to heal prior to the initiation of dialysis, thereby avoiding complications of leaking and infection. The minimum timeframe for healing is about two weeks. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28153?source=see_link\">",
"       \"Chronic peritoneal dialysis in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60773527\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparations for renal replacement therapy (RRT) should be initiated in children with chronic kidney disease (CKD) when their glomerular filtration rate falls below 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 (stage 4 CKD).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Estimated incidences for end-stage kidney disease (stage 5 CKD) and initiation of RRT vary between 4 and 15 per million children worldwide. This variability is thought to be due to genetic and environmental factors, as well as the ability to detect ESKD and provide RRT to children with significant renal impairment. (See",
"      <a class=\"local\" href=\"#H363124244\">",
"       'Incidence of ESKD and RRT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of pediatric ESKD is congenital anomalies of the kidney and urinary tract (CAKUT). The proportion of cases with CAKUT decreases with increasing age due to the increasing incidence of acquired glomerular disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=see_link&amp;anchor=H6#H6\">",
"       \"Epidemiology, etiology, and course of chronic kidney disease in children\", section on 'Etiology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=see_link\">",
"       \"Overview of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The choices of RRT in children with CKD include renal transplantation, hemodialysis, and peritoneal dialysis. (See",
"      <a class=\"local\" href=\"#H363124528\">",
"       'Choice of RRT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Preemptive transplantation is the preferred RRT, because it is associated with better long-term outcomes (eg, growth, development, quality of life, and mortality) and less disruption to patients and their families. (See",
"      <a class=\"local\" href=\"#H445803611\">",
"       'Preemptive renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When preemptive transplantation is not an option, the choice between the two forms of dialysis for ESKD is generally dictated by technical, social, and compliance issues, and family preference. (See",
"      <a class=\"local\" href=\"#H445803487\">",
"       'Choice of dialysis modality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As in adults, some form of RRT is generally needed in children when the GFR falls below 15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2 (stage 5 CKD); although, RRT may be initiated earlier in children primarily to maintain normal growth and to manage metabolic abnormalities that are unresponsive to other medical interventions. However, some children with maintained urine output may continue without dialysis for years if attention is paid to their nutritional and therapeutic management. (See",
"      <a class=\"local\" href=\"#H118550707\">",
"       'Timing of RRT'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of the management of chronic kidney disease in children\", section on 'Chronic kidney disease complications'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/2\">",
"      Srivastava T, Alon US, Althahabi R, Garg U. Impact of standardization of creatinine methodology on the assessment of glomerular filtration rate in children. Pediatr Res 2009; 65:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/3\">",
"      Schwartz GJ, Mu&ntilde;oz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/4\">",
"      Warady BA, Chadha V. Chronic kidney disease in children: the global perspective. Pediatr Nephrol 2007; 22:1999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/5\">",
"      Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. Pediatr Nephrol 2012; 27:363.",
"     </a>",
"    </li>",
"    <li>",
"     US Renal Data System. The Concise 2009 Annual Data Report: Atlas of Chronic kidney disease and End-stage Renal Disease in the US. National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/7\">",
"      Lewis MA, Shaw J, Sinha M, et al. UK Renal Registry 11th Annual Report (December 2008): Chapter 13 Demography of the UK paediatric renal replacement therapy population. Nephron Clin Pract 2009; 111 Suppl 1:c257.",
"     </a>",
"    </li>",
"    <li>",
"     McTaggart S, Kennedy S, McDonald S, et al. Paediatric Report. ANZDATA Registry 2009 Report. Available at: file://www.anzdata.org.au/anzdata/AnzdataReport/32ndReport/Ch11.pdf. (Accessed on February 22, 2011).",
"    </li>",
"    <li>",
"     NAPRTCS: 2008 Annual Report, Rockville, MD. file://www.emmes.com/study/ped/annlrept/Annual%20Report%20-2008.pdf (Accessed on March 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/10\">",
"      Gillen DL, Stehman-Breen CO, Smith JM, et al. Survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation. Am J Transplant 2008; 8:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/11\">",
"      Kramer A, Stel VS, Tizard J, et al. Characteristics and survival of young adults who started renal replacement therapy during childhood. Nephrol Dial Transplant 2009; 24:926.",
"     </a>",
"    </li>",
"    <li>",
"     NAPRTCS 2010 Annual Transplant report. https://web.emmes.com/study/ped/annlrept/2010_Report.pdf.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/13\">",
"      Sadowski RH, Harmon WE, Jabs K. Acute hemodialysis of infants weighing less than five kilograms. Kidney Int 1994; 45:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12774/abstract/14\">",
"      Carey WA, Talley LI, Sehring SA, et al. Outcomes of dialysis initiated during the neonatal period for treatment of end-stage renal disease: a North American Pediatric Renal Trials and Collaborative Studies special analysis. Pediatrics 2007; 119:e468.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16179 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-5917900B73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12774=[""].join("\n");
var outline_f12_30_12774=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H60773527\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118550482\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118550572\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H363124244\">",
"      INCIDENCE OF ESKD AND RRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H363124528\">",
"      CHOICE OF RRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H445803611\">",
"      Preemptive renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H445803487\">",
"      Choice of dialysis modality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H118550707\">",
"      TIMING OF RRT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60773527\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/16179\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16179|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/1/40990\" title=\"figure 1\">",
"      Causes CKD children age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/16179|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/4/22603\" title=\"table 1\">",
"      Stages of CKD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?23/40/24193?source=related_link\" title=\"calculator 1\">",
"      Calculator: Glomerular filtration rate estimate by Schwartz formula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/31/28153?source=related_link\">",
"      Chronic peritoneal dialysis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/9/11418?source=related_link\">",
"      Clinical presentation and evaluation of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22154?source=related_link\">",
"      Complications of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/18/26919?source=related_link\">",
"      Epidemiology, etiology, and course of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/63/23543?source=related_link\">",
"      General principles of kidney transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9242?source=related_link\">",
"      Hemodialysis for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22472?source=related_link\">",
"      Overview of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/17/32026?source=related_link\">",
"      Overview of the management of chronic kidney disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_30_12775="Micrograph ganglioneuroma";
var content_f12_30_12775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F77698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F77698&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Micrograph ganglioneuroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 494px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Photomicrograph of a tumor that was removed from the L2-3 nerve root. The spindle cells and collagenous background resemble neurofibroma. However, several multinucleated, dysplastic ganglion cells can be seen interspersed amidst the neurofibromatous background (arrows). Therefore, this tumor would be considered a ganglioneuroma. H&amp;E, x100. B) A higher-power view of a focal cluster of dysplastic ganglion cells (arrows). H&amp;E, x600.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John E Donahue, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12775=[""].join("\n");
var outline_f12_30_12775=null;
var title_f12_30_12776="Initial evaluation and management of abdominal stab wounds in adults";
var content_f12_30_12776=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial evaluation and management of abdominal stab wounds in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12776/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12776/contributors\">",
"     Michael A Puskarich, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12776/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12776/contributors\">",
"     Robert S Hockberger, MD, FACEP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12776/contributors\">",
"     Maria E Moreira, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12776/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12776/contributors\">",
"     Jonathan Grayzel, MD, FAAEM",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/30/12776/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergency clinicians manage stab wound (SW) injuries now more than ever. While in the past surgical dictum mandated exploratory laparotomy for all patients with abdominal SWs, new diagnostic techniques and therapeutic modalities have rendered that dogmatic approach obsolete.",
"   </p>",
"   <p>",
"    This topic review will discuss the evaluation and management of abdominal stab wounds. Initial trauma management, blunt abdominal trauma, abdominal gunshot wounds, and other aspects of trauma management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=see_link\">",
"     \"Initial evaluation and management of blunt abdominal trauma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=see_link\">",
"     \"Initial evaluation and management of abdominal gunshot wounds in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While three times more prevalent than gunshot wounds, stab wounds (SW) are typically less invasive due to their lower velocity, and therefore, associated morbidity and mortality is decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/1\">",
"     1",
"    </a>",
"    ]. In children and adults alike, the liver is the organ most often injured. Small bowel injuries follow close behind [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any instrument that can impale may inflict a stab wound (SW). Typically these are narrow and sharp, such as a knife, scissor, arrow, pen, fence post, ice pick, coat hanger, or an animal horn. The instrument's path and depth may injure any tissue it traverses, including skin, fascia, solid organ, hollow viscus, and even bone.",
"   </p>",
"   <p>",
"    The area most often injured is the upper abdomen, left upper quadrant greater than right. Multiple SWs are present in up to 20 percent of patients and 10 percent of SWs may involve the chest [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. If the wound is close to the lower chest, clinicians must consider and evaluate diaphragmatic and intrathoracic injuries in addition to intraabdominal injury. Potential intrathoracic injuries include pneumothorax and pericardial tamponade. Peritoneal violation with intraabdominal injury occurs in greater than 40 percent of SWs to the flank and up to 15 percent of those to the back.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANATOMIC ZONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal cavity is divided into four anatomic zones (",
"    <a class=\"graphic graphic_figure graphicRef64644 \" href=\"UTD.htm?17/58/18340\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef51176 \" href=\"UTD.htm?37/62/38884\">",
"     figure 2",
"    </a>",
"    ). The",
"    <strong>",
"     anterior abdomen",
"    </strong>",
"    is bound by the anterior axillary lines extending from the costal margins to the groin creases. The nipple line (fourth intercostal space) anteriorly and the tips of the scapulae (seventh intercostal space) and the inferior costal margin posteriorly demarcate the cephalad portion of the",
"    <strong>",
"     thoracoabdominal",
"    </strong>",
"    area. The caudad portion is bound by the inferior costal margin. Wounds in this general region pose significant threat, as injury to the chest, mediastinum, and abdomen are all possible because of the path of the weapon and movement of the diaphragm. The",
"    <strong>",
"     flanks",
"    </strong>",
"    are separated on each side by the inferior costal margins and iliac crests, and the anterior and posterior axillary lines. The",
"    <strong>",
"     back",
"    </strong>",
"    is defined as the area between the posterior axillary lines, the inferior scapular tips (seventh intercostals space), and the iliac crest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Answers to the following questions help to guide the clinician in assessing potential injuries:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What instrument was used?",
"     </li>",
"     <li>",
"      How long and how wide was the instrument?",
"     </li>",
"     <li>",
"      How was the patient positioned during the stabbing?",
"     </li>",
"     <li>",
"      What path did the implement travel?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     METHODS OF EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Initial assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with gunshot wounds (GSW), it is vitally important to completely undress any patient who sustains a stab wound (SW). SWs can often be obscured by body habitus, clothing, or bleeding, or be \"hidden\" in the axilla, scalp, or groin. The clinician should be wary of lacerations reported to be, or that appear to be, from blunt trauma. As an example, linear lacerations to the face may be interpreted as superficial when caused by a blunt mechanism, but in fact represent stab wounds with intracranial penetration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Local wound exploration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stab wounds (SWs) are often amenable to local wound exploration (LWE) to evaluate their depth and tract [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/6\">",
"     6",
"    </a>",
"    ]. This is quickly and safely performed at the bedside in patients with SWs to the abdomen, flank, or back, but not over the chest wall due to underlying viscera (lungs) and intercostal vessels. This procedure, better undertaken by two individuals, requires local anesthesia and both sharp and blunt dissection until the bottom of the wound is clearly visualized. Blunt probing with fingers or cotton swabs is an inaccurate and potentially dangerous means of evaluating the wound tract, and may lead to a false conclusion that the peritoneum was not violated [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For anterior SWs, if the rectus fascia is completely visualized and not violated (ie, the bottom of the wound is completely visualized and is anterior to the posterior rectus fascia), then patients may be discharged after appropriate wound care, assuming no additional or extraabdominal injuries are present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/6,8,9\">",
"     6,8,9",
"    </a>",
"    ]. Heavy muscle, obesity, or the presence of multiple wounds or other injuries can impede successful LWE [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/7,10,11\">",
"     7,10,11",
"    </a>",
"    ]. If the posterior fascia is not clearly and completely seen, peritoneal injury cannot be ruled out and further testing must ensue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plain film radiographs add little to the management of abdominal SWs. If free intraperitoneal air is seen on an upright chest or lateral decubitus x-ray, then the peritoneal cavity has been violated, but this does not confirm hollow viscus injury. Thus, plain radiographs lack sensitivity and specificity and are rarely employed in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multidetector CT is a noninvasive and fast modality that enables clinicians to identify peritoneal penetration and delineate visceral injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. A systematic review and observational studies cite a sensitivity of up to 97 percent coupled with a specificity of up to 98 percent for identification of peritoneal violation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/13\">",
"     13",
"    </a>",
"    ], and a sensitivity of 94 percent and specificity of 95 percent for predicting the need for laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/12,16,17\">",
"     12,16,17",
"    </a>",
"    ]. However, the positive predictive value may be more limited [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/17\">",
"     17",
"    </a>",
"    ]. CT also enables the identification of intraperitoneal injuries, such as hepatic lacerations, that may be amenable to nonoperative management [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although many studies advocate using triple contrast (intravenous, oral, and rectal), the advent of high-resolution, multidetector CT scanners makes this approach unnecessary in most cases. Oral and rectal contrast may be reserved for patients with possible colorectal injury.",
"   </p>",
"   <p>",
"    One prospective observational study suggests that CT with IV contrast alone can identify those hemodynamically stable patients with penetrating abdominal trauma in whom nonoperative management of organ injury can be successful [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/18\">",
"     18",
"    </a>",
"    ]. In this study, hollow viscus injury was suspected if there was free intraperitoneal or retroperitoneal air, free intraperitoneal fluid in the absence of solid organ injury, localized bowel wall thickening, or a bullet tract close to a hollow viscus with surrounding hematoma. Patients with these findings proceeded to exploratory laparotomy.",
"   </p>",
"   <p>",
"    Another prospective observational study, although it dealt solely with gunshot rather than stab wounds, found that CT with IV contrast alone had a sensitivity and specificity for detecting intraabdominal injury requiring laparotomy similar to CT with triple contrast [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/16\">",
"     16",
"    </a>",
"    ]. The researchers' protocol reserved use of oral and rectal contrast for specific patient subpopulations, thereby reducing the time needed to perform CT.",
"   </p>",
"   <p>",
"    Even with a negative initial CT scan, patients with a high likelihood for diaphragmatic, bowel, or pancreatic injury should have further testing, or observation and serial examinations, as these injuries are the ones most frequently missed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/12,18,19\">",
"     12,18,19",
"    </a>",
"    ]. However, the accuracy of multidetector CT scans in diagnosing diaphragmatic injury is improving [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of ultrasound (US) in penetrating abdominal trauma continues to evolve. While it is not routinely used to diagnose peritoneal penetration, a small preliminary study using the US probe to assess fascial violation deep to the SW demonstrated excellent specificity but suboptimal sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    US is frequently used to perform the Focused Abdominal Sonography for Trauma (FAST) examination and determine the presence of hemopericardium, hemoperitoneum, pneumothorax, or some combination thereof. The use of ultrasound in evaluating patients with abdominal trauma is described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=see_link\">",
"     \"Emergency ultrasound in adults with abdominal and thoracic trauma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The FAST exam is particularly valuable in the initial assessment of a patient with a low chest or upper abdominal SW who is hemodynamically unstable. However, for detecting intraabdominal injury from penetrating trauma, the FAST exam is specific but shows limited sensitivity. In hemodynamically stable patients with a positive FAST, other diagnostic modalities such as CT or diagnostic laparoscopy can identify specific injuries and aid management. In those with a negative FAST, injury cannot be excluded and other diagnostic modalities must be employed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Diagnostic peritoneal tap and lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although invasive, diagnostic peritoneal lavage (DPL) remains a rapid and easily performed bedside test that offers information about peritoneal penetration and injury to solid organs, bowel, and the diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While there is continued debate over the red blood cell count threshold for detecting injury, most agree that the presence of greater than 10,000 red blood cells per high-powered field",
"    <span class=\"nowrap\">",
"     (RBCs/HPF)",
"    </span>",
"    or the aspiration of 10 mL of gross blood indicates visceral injury in penetrating abdominal wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/23,24,26\">",
"     23,24,26",
"    </a>",
"    ]. A criterion range of 5000 to 10,000",
"    <span class=\"nowrap\">",
"     RBCs/HPF",
"    </span>",
"    should be used to determine the presence of injury in thoracoabdominal wounds, as this lowered threshold allows detection of isolated diaphragmatic or small bowel injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/23,27\">",
"     23,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The authors of one retrospective study of 195 patients with stab wounds to the anterior chest or abdomen suggest that using the criterion of &gt;100,000",
"    <span class=\"nowrap\">",
"     RBCs/HPF,",
"    </span>",
"    along with the presence of &gt;500 white blood cells",
"    <span class=\"nowrap\">",
"     (WBCs)/HPF,",
"    </span>",
"    bile, or amylase, to determine a positive DPL, decreases the false positive rate, thereby lowering nontherapeutic laparotomy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/28\">",
"     28",
"    </a>",
"    ]. However, diagnosis can be delayed using this method, as white blood cell counts do not become positive until approximately six hours from injury and laboratory analysis would be required to detect bile or amylase. Additional prospective studies are needed to validate this proposed change in threshold.",
"   </p>",
"   <p>",
"    DPL may be best employed in combination with serial physical examinations in patients selected for initial nonoperative management [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/11,29,30\">",
"     11,29,30",
"    </a>",
"    ]. However, its use is decreasing as other less invasive tests become increasingly accurate and offer similar information regarding organ and hollow viscus injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diagnostic laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic laparoscopy (DL) is most useful for inspecting the diaphragm in thoracoabdominal wounds, although some studies suggest it may be useful in evaluating the depth of wound tracts and identifying visceral injury in patients with equivocal peritoneal penetration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. In addition, some diaphragmatic and visceral injuries may be amenable to repair using DL, avoiding the need for exploratory laparotomy and thereby decreasing length of stay, morbidity, and cost. DL remains inadequate for identifying hollow viscus and retroperitoneal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. While in some medical centers DL is used as a screening tool for patients with abdominal SWs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/32,36\">",
"     32,36",
"    </a>",
"    ], for most it represents a novel approach and controversy about its use persists [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determining the need for immediate laparotomy represents the central task in managing the patient with an abdominal stab wound (SW). A basic management algorithm is provided (",
"    <a class=\"graphic graphic_algorithm graphicRef52480 \" href=\"UTD.htm?16/60/17358\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After providing initial resuscitation based upon protocols from Advanced Trauma Life Support (ATLS&reg;), emergency physicians and trauma surgeons determine the need for laparotomy using a combination of physical examination, computed tomography (CT), ultrasound (US), diagnostic peritoneal lavage (DPL), laparoscopy, and thoracoscopy. No diagnostic strategy is foolproof. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=see_link\">",
"     \"Initial management of trauma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with hemodynamic instability or unequivocal peritoneal signs are taken immediately to the operating suite, as are patients with evisceration in most trauma centers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/39\">",
"     39",
"    </a>",
"    ]. Hemodynamically stable patients are evaluated for the presence of peritoneal penetration and intraabdominal injury, most often using CT. Possible intrathoracic, mediastinal, and retroperitoneal injuries are assessed based upon wound location and clinical findings. Study results and patient condition determine management. In patients undergoing observation, findings from serial examinations and possibly repeat imaging determine management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Indications for mandatory laparotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identifying which patients with penetrating abdominal trauma require immediate surgical intervention is the central task of evaluation. Historically, trauma clinicians agreed that immediate laparotomy was indicated in the presence of hemodynamic instability, evisceration, or unequivocal peritoneal signs on physical examination [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/7,10,29-31,40-44\">",
"     7,10,29-31,40-44",
"    </a>",
"    ]. At many centers, these signs continue to be indications for laparotomy. However, using these criteria, up to one-third of patients with bowel or mesentery evisceration undergo a nontherapeutic laparotomy.",
"   </p>",
"   <p>",
"    One retrospective study challenges this dogmatic approach for hemodynamically stable patients with evisceration, advocating instead for admission and serial examinations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/40\">",
"     40",
"    </a>",
"    ]. The authors cite lower nontherapeutic laparotomy rates and shorter lengths of stay for patients initially managed nonoperatively. Prospective randomized trials are needed to validate this approach.",
"   </p>",
"   <p>",
"    Signs of gastrointestinal hemorrhage suggest gastroduodenal or colorectal injury, particularly if the site of entry and suspected weapon path are consistent, and generally warrant laparotomy without further investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/2\">",
"     2",
"    </a>",
"    ]. An implement in situ (ie, a weapon protruding from the patient's body) ordinarily prompts laparotomy, even in stable patients, in case the implement rests inside an intraperitoneal vessel, such that removal wound lead to hemorrhage. However, such a scenario is extremely unlikely. Therefore, high risk surgical candidates and pregnant patients, for whom laparotomy puts the fetus at risk, may undergo removal of the implement without general anesthesia but in the operating suite in case they deteriorate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Peritoneal violation",
"    </span>",
"    &nbsp;&mdash;&nbsp;If no indications for mandatory laparotomy exist, additional examinations and studies are performed to identify peritoneal violation and intraabdominal injury. These injuries can be identified using local wound exploration (LWE), CT, diagnostic peritoneal lavage (DPL), diagnostic laparoscopy (DL), or ultrasound (US) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/7,8,10,16,29,41,42\">",
"     7,8,10,16,29,41,42",
"    </a>",
"    ]. The choice of modality differs according to clinician preference, SW location, and resource availability.",
"   </p>",
"   <p>",
"    Peritoneal violation occurs in up to 50 to 70 percent of abdominal SWs, but only half of those with peritoneal violation sustain an intraabdominal injury requiring operative intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Thus, only 25 to 33 percent of patients with abdominal SWs require laparotomy.",
"   </p>",
"   <p>",
"    If LWE is performed and no peritoneal violation has occurred, the patient may be discharged safely after local wound care. Patients with abdominal SWs and negative CT, DPL, or DL still require observation for 12 to 24 hours, as none of these tests has 100 percent sensitivity to rule out intraperitoneal, particularly hollow viscus, injury. A period of observation also allows time for detection of post-test complications in those managed with DPL or DL.",
"   </p>",
"   <p>",
"    Some data suggest a subset of patients may be safely discharged immediately following diagnostic evaluation in the emergency department (ED). As an example, one retrospective review of patients with penetrating abdominal trauma treated in an urban trauma center found that few patients discharged following a negative workup sustained adverse outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition to a general history and physical examination, workups consisted of some combination of LWE, CT, and serial examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Selective nonoperative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;With increased use of the more sophisticated diagnostic modalities described above, more trauma centers are managing nonoperatively those patients without indications for immediate laparotomy. Nontherapeutic and negative laparotomy rates, as well as overall lengths of hospital stay and cost, are reduced with this approach [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/3,7,9,10,16,44,45\">",
"     3,7,9,10,16,44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with an abdominal SW who are initially asymptomatic but ultimately manifest signs of a significant intraperitoneal injury do so within the first several hours of presentation. When a SW is extraperitoneal as determined by local wound exploration (LWE), in selected circumstances (eg, no other serious injury is present), the patient may be discharged without further testing or observation.&nbsp;When LWE cannot be performed or if it is indeterminate, the patient requires observation. Delayed presentations of intraperitoneal injury do occur in such cases, and therefore, we suggest an observation period of at least 12 to 24 hours prior to discharge.",
"   </p>",
"   <p>",
"    Medical centers using a nonoperative approach must be able to provide frequent serial examinations, especially in patients who do not receive further diagnostic testing, as patient outcomes are better with early operative intervention when peritonitis or hemodynamic instability develops.",
"   </p>",
"   <p>",
"    The idea of selective nonoperative management of abdominal SWs evolved as negative laparotomy rates approached 30 percent in the post-World War II era. An important impetus for this approach was a seminal study published in 1960 describing patients with abdominal SWs who were selected for serial observation and underwent laparotomy only if peritoneal signs or hemodynamic instability developed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23308870\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Broad spectrum antibiotics are generally given to patients with penetrating abdominal injury requiring surgical management; routine antibiotic administration is not warranted in most injured patients, including those with penetrating abdominal injury, who are managed nonoperatively. The use of prophylactic antibiotics in the setting of trauma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=see_link&amp;anchor=H172458237#H172458237\">",
"     \"Overview of inpatient management in the adult trauma patient\", section on 'Antibiotics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Flank and back",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of structures injured from penetrating wounds to the flank and back is difficult. Stab wounds (SW) to these regions can injure both retroperitoneal and intraperitoneal structures. Approximately 40 percent of penetrating flank wounds result in significant internal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. Triple contrast CT (3CT) has become the diagnostic modality of choice for stable patients and may allow for safe triage to nonoperative management [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/44,46,47\">",
"     44,46,47",
"    </a>",
"    ]. Local wound exploration (LWE), ultrasound (US), diagnostic peritoneal lavage (DPL), and diagnostic laparoscopy (DL) are not ideal for evaluation of retroperitoneal structures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Thoracoabdominal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracoabdominal wounds present a diagnostic challenge as movement of the diaphragm makes prediction of the SW tract difficult. If the wound is close to the lower chest, intrathoracic and diaphragmatic injuries must be considered and evaluated in addition to intraabdominal injury. Potential intrathoracic injuries include pneumothorax and pericardial tamponade.",
"   </p>",
"   <p>",
"    The morbidity and mortality associated with missed diaphragmatic injury on the left side is high (the liver generally prevents small bowel herniation on the right side). Therefore, exploratory laparotomy for SW in this location is mandatory at a few trauma centers. However, most trauma experts feel the negative laparotomy rate when using this approach is unacceptably high. Other experts choose to perform DPL, using the lower threshold of 5000 red blood cells per high powered field",
"    <span class=\"nowrap\">",
"     (RBCs/HPF)",
"    </span>",
"    as the criterion for exploratory laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Diagnostic peritoneal tap and lavage'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28009?source=see_link\">",
"     \"Recognition and management of diaphragmatic injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If diaphragmatic injury is a concern, multidetector CT scan, diagnostic laparoscopy (DL), or thoracoscopy may be used to determine the presence or absence of such injury. As DL becomes more available and clinicians more adept at its use, it may become the mainstay of evaluation for diaphragmatic injury in patients with thoracoabdominal SWs [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/31,35,36\">",
"     31,35,36",
"    </a>",
"    ]. The accuracy of multidetector CT scans in diagnosing diaphragmatic injury is improving [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12776/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Diagnostic laparoscopy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Computed tomography'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stab wounds (SW) most often injure the liver, with small bowel injuries a close second. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ask the patient what instrument was used, how long it was, how wide it was, how he or she was positioned during the stabbing, and what path the implement traveled. Undress completely any patient who sustains a SW. SWs can often be obscured by body habitus, clothing, or bleeding, or be \"hidden\" in the axilla, scalp, or groin. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Initial assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SWs to the abdomen, flank, or back are often amenable to local wound exploration (LWE) to evaluate their depth and tract. If body habitus, multiple wounds, other injuries, or difficulty in performing LWE impedes visualization of the complete depth of the wound, then peritoneal injury cannot be ruled out and further testing must ensue. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Local wound exploration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plain film radiographs add little to the management of abdominal SWs. Ultrasound has limited sensitivity for detecting intraabdominal injury from penetrating trauma, but may help rule out life-threatening hemopericardium. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CT is a noninvasive and fast modality that enables identification of peritoneal penetration and delineation of visceral injury. Patients with a high likelihood for diaphragmatic, bowel, or pancreatic injury should have further testing, or observation and serial examinations, even with a negative initial CT scan, as these injuries are missed most frequently. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Computed tomography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic peritoneal lavage (DPL) is a rapid and easily performed bedside test that offers information about peritoneal penetration and injury to solid organs, bowel, and the diaphragm. There is continued debate over the red blood cell count threshold for detecting injury, but most agree that greater than 10,000 red blood cells per high-powered field",
"      <span class=\"nowrap\">",
"       (RBCs/HPF)",
"      </span>",
"      or the aspiration of 10 mL of gross blood indicates visceral injury. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnostic peritoneal tap and lavage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for emergent laparotomy include: hemodynamic instability, unequivocal peritoneal signs on physical examination, signs of gastrointestinal hemorrhage, and implement in situ. Evisceration of bowel or mesentery is an indication for immediate laparotomy at most trauma centers (",
"      <a class=\"graphic graphic_algorithm graphicRef52480 \" href=\"UTD.htm?16/60/17358\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Indications for mandatory laparotomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients without obvious need for emergent laparotomy, selective nonoperative management is common practice. Most clinicians couple frequent physical examination with CT, diagnostic laparoscopy (DL), or diagnostic peritoneal lavage (DPL) to identify those patients who might benefit from surgical intervention, but do not meet criteria for mandatory exploratory laparotomy on initial presentation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Peritoneal violation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Selective nonoperative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Flank, back, and thoracoabdominal injuries may involve more than one anatomic space and can be difficult to manage. Stable patients with stab wounds to the flank or back are generally evaluated using triple contrast CT. The morbidity and mortality associated with missed diaphragmatic injury on the left side is high. Patients with thoracoabdominal injury require thorough investigation, possibly with DL or thoracoscopy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Special considerations'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5225339\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the untimely death of John Marx, MD, who passed away in July 2012. We wish to acknowledge Dr. Marx's dedication and his many contributions to UpToDate, in particular, his work as editor-in-chief for Emergency Medicine and as a section editor and author for Adult Trauma.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/1\">",
"      Nicholas JM, Rix EP, Easley KA, et al. Changing patterns in the management of penetrating abdominal trauma: the more things change, the more they stay the same. J Trauma 2003; 55:1095.",
"     </a>",
"    </li>",
"    <li>",
"     Marx JA, Isenhour JL. Abdominal trauma. In: Rosen's Emergency Medicine: Concepts and Clinical Practice, 6th, Marx JA.  (Ed), Mosby, Philadelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/3\">",
"      Boyle EM Jr, Maier RV, Salazar JD, et al. Diagnosis of injuries after stab wounds to the back and flank. J Trauma 1997; 42:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/4\">",
"      MOSS LK, SCHMIDT FE, CREECH O Jr. Analysis of 550 stab wounds of the abdomen. Am Surg 1962; 28:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/5\">",
"      McCarthy MC, Lowdermilk GA, Canal DF, Broadie TA. Prediction of injury caused by penetrating wounds to the abdomen, flank, and back. Arch Surg 1991; 126:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/6\">",
"      Cothren CC, Moore EE, Warren FA, et al. Local wound exploration remains a valuable triage tool for the evaluation of anterior abdominal stab wounds. Am J Surg 2009; 198:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/7\">",
"      Rosenthal RE, Smith J, Walls RM, et al. Stab wounds to the abdomen: failure of blunt probing to predict peritoneal penetration. Ann Emerg Med 1987; 16:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/8\">",
"      Biffl WL, Kaups KL, Cothren CC, et al. Management of patients with anterior abdominal stab wounds: a Western Trauma Association multicenter trial. J Trauma 2009; 66:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/9\">",
"      Biffl WL, Kaups KL, Pham TN, et al. Validating the Western Trauma Association algorithm for managing patients with anterior abdominal stab wounds: a Western Trauma Association multicenter trial. J Trauma 2011; 71:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/10\">",
"      Conrad MF, Patton JH Jr, Parikshak M, Kralovich KA. Selective management of penetrating truncal injuries: is emergency department discharge a reasonable goal? Am Surg 2003; 69:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/11\">",
"      Tsikitis V, Biffl WL, Majercik S, et al. Selective clinical management of anterior abdominal stab wounds. Am J Surg 2004; 188:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/12\">",
"      Chiu WC, Shanmuganathan K, Mirvis SE, Scalea TM. Determining the need for laparotomy in penetrating torso trauma: a prospective study using triple-contrast enhanced abdominopelvic computed tomography. J Trauma 2001; 51:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/13\">",
"      Shanmuganathan K, Mirvis SE, Chiu WC, et al. Penetrating torso trauma: triple-contrast helical CT in peritoneal violation and organ injury--a prospective study in 200 patients. Radiology 2004; 231:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/14\">",
"      Soto JA, Morales C, M&uacute;nera F, et al. Penetrating stab wounds to the abdomen: use of serial US and contrast-enhanced CT in stable patients. Radiology 2001; 220:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/15\">",
"      Salim A, Sangthong B, Martin M, et al. Use of computed tomography in anterior abdominal stab wounds: results of a prospective study. Arch Surg 2006; 141:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/16\">",
"      Velmahos GC, Constantinou C, Tillou A, et al. Abdominal computed tomographic scan for patients with gunshot wounds to the abdomen selected for nonoperative management. J Trauma 2005; 59:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/17\">",
"      Goodman CS, Hur JY, Adajar MA, Coulam CH. How well does CT predict the need for laparotomy in hemodynamically stable patients with penetrating abdominal injury? A review and meta-analysis. AJR Am J Roentgenol 2009; 193:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/18\">",
"      Demetriades D, Hadjizacharia P, Constantinou C, et al. Selective nonoperative management of penetrating abdominal solid organ injuries. Ann Surg 2006; 244:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/19\">",
"      Velmahos GC, Demetriades D, Toutouzas KG, et al. Selective nonoperative management in 1,856 patients with abdominal gunshot wounds: should routine laparotomy still be the standard of care? Ann Surg 2001; 234:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/20\">",
"      Stein DM, York GB, Boswell S, et al. Accuracy of computed tomography (CT) scan in the detection of penetrating diaphragm injury. J Trauma 2007; 63:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/21\">",
"      Murphy JT, Hall J, Provost D. Fascial ultrasound for evaluation of anterior abdominal stab wound injury. J Trauma 2005; 59:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/22\">",
"      Gonzalez RP, Ickler J, Gachassin P. Complementary roles of diagnostic peritoneal lavage and computed tomography in the evaluation of blunt abdominal trauma. J Trauma 2001; 51:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/23\">",
"      Nagy KK, Roberts RR, Joseph KT, et al. Experience with over 2500 diagnostic peritoneal lavages. Injury 2000; 31:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/24\">",
"      Sriussadaporn S, Pak-art R, Pattaratiwanon M, et al. Clinical uses of diagnostic peritoneal lavage in stab wounds of the anterior abdomen: a prospective study. Eur J Surg 2002; 168:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/25\">",
"      Cha JY, Kashuk JL, Sarin EL, et al. Diagnostic peritoneal lavage remains a valuable adjunct to modern imaging techniques. J Trauma 2009; 67:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/26\">",
"      Brakenridge SC, Nagy KK, Joseph KT, et al. Detection of intra-abdominal injury using diagnostic peritoneal lavage after shotgun wound to the abdomen. J Trauma 2003; 54:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/27\">",
"      Henneman PL, Marx JA, Moore EE, et al. Diagnostic peritoneal lavage: accuracy in predicting necessary laparotomy following blunt and penetrating trauma. J Trauma 1990; 30:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/28\">",
"      Thacker LK, Parks J, Thal ER. Diagnostic peritoneal lavage: is 100,000 RBCs a valid figure for penetrating abdominal trauma? J Trauma 2007; 62:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/29\">",
"      Ertekin C, Yanar H, Taviloglu K, et al. Unnecessary laparotomy by using physical examination and different diagnostic modalities for penetrating abdominal stab wounds. Emerg Med J 2005; 22:790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/30\">",
"      Alzamel HA, Cohn SM. When is it safe to discharge asymptomatic patients with abdominal stab wounds? J Trauma 2005; 58:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/31\">",
"      Pryor JP, Reilly PM, Dabrowski GP, et al. Nonoperative management of abdominal gunshot wounds. Ann Emerg Med 2004; 43:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/32\">",
"      Ahmed N, Whelan J, Brownlee J, et al. The contribution of laparoscopy in evaluation of penetrating abdominal wounds. J Am Coll Surg 2005; 201:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/33\">",
"      Friese RS, Coln CE, Gentilello LM. Laparoscopy is sufficient to exclude occult diaphragm injury after penetrating abdominal trauma. J Trauma 2005; 58:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/34\">",
"      Lepp&auml;niemi A, Haapiainen R. Occult diaphragmatic injuries caused by stab wounds. J Trauma 2003; 55:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/35\">",
"      Poole GV, Thomae KR, Hauser CJ. Laparoscopy in trauma. Surg Clin North Am 1996; 76:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/36\">",
"      Simon RJ, Rabin J, Kuhls D. Impact of increased use of laparoscopy on negative laparotomy rates after penetrating trauma. J Trauma 2002; 53:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/37\">",
"      Lepp&auml;niemi A, Haapiainen R. Diagnostic laparoscopy in abdominal stab wounds: a prospective, randomized study. J Trauma 2003; 55:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/38\">",
"      Kopelman TR, O'Neill PJ, Macias LH, et al. The utility of diagnostic laparoscopy in the evaluation of anterior abdominal stab wounds. Am J Surg 2008; 196:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/39\">",
"      Como JJ, Bokhari F, Chiu WC, et al. Practice management guidelines for selective nonoperative management of penetrating abdominal trauma. J Trauma 2010; 68:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/40\">",
"      Arikan S, Kocakusak A, Yucel AF, Adas G. A prospective comparison of the selective observation and routine exploration methods for penetrating abdominal stab wounds with organ or omentum evisceration. J Trauma 2005; 58:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/41\">",
"      Nance FC, Wennar MH, Johnson LW, et al. Surgical judgment in the management of penetrating wounds of the abdomen: experience with 2212 patients. Ann Surg 1974; 179:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/42\">",
"      Demetriades D, Rabinowitz B. Indications for operation in abdominal stab wounds. A prospective study of 651 patients. Ann Surg 1987; 205:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/43\">",
"      SHAFTAN GW. Indications for operation in abdominal trauma. Am J Surg 1960; 99:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/44\">",
"      Ginzburg E, Carrillo EH, Kopelman T, et al. The role of computed tomography in selective management of gunshot wounds to the abdomen and flank. J Trauma 1998; 45:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/45\">",
"      Plackett TP, Fleurat J, Putty B, et al. Selective nonoperative management of anterior abdominal stab wounds: 1992-2008. J Trauma 2011; 70:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/46\">",
"      Albrecht RM, Vigil A, Schermer CR, et al. Stab wounds to the back/flank in hemodynamically stable patients: evaluation using triple-contrast computed tomography. Am Surg 1999; 65:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12776/abstract/47\">",
"      Pham TN, Heinberg E, Cuschieri J, et al. The evolution of the diagnostic work-up for stab wounds to the back and flank. Injury 2009; 40:48.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 356 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12776=[""].join("\n");
var outline_f12_30_12776=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANATOMIC ZONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      METHODS OF EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Initial assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Local wound exploration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ultrasound",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Diagnostic peritoneal tap and lavage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diagnostic laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Indications for mandatory laparotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Peritoneal violation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Selective nonoperative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23308870\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Flank and back",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Thoracoabdominal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5225339\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/356\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/356|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?16/60/17358\" title=\"algorithm 1\">",
"      Abdominl stab wound management algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/356|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/58/18340\" title=\"figure 1\">",
"      Anatomic zones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/62/38884\" title=\"figure 2\">",
"      Abdomen anatomy adult",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/30/7658?source=related_link\">",
"      Emergency ultrasound in adults with abdominal and thoracic trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/54/3943?source=related_link\">",
"      Initial evaluation and management of abdominal gunshot wounds in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19545?source=related_link\">",
"      Initial evaluation and management of blunt abdominal trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/11/35002?source=related_link\">",
"      Initial management of trauma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/21/31066?source=related_link\">",
"      Overview of inpatient management in the adult trauma patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28009?source=related_link\">",
"      Recognition and management of diaphragmatic injury in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_30_12777="Insulinoma";
var content_f12_30_12777=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Insulinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12777/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12777/contributors\">",
"     F John Service, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12777/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12777/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12777/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12777/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/30/12777/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low blood glucose concentrations were recognized as a feature of several diseases in the 19th century. However, it was not until insulin became available for the treatment of diabetes mellitus in the early 1920s that clinical events similar to those arising from overtreatment with insulin were identified in nondiabetic persons. This observation led to the postulation of a new disease entity called hyperinsulinism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Support for the existence of hyperinsulinism was provided by finding a malignant pancreatic islet-cell tumor in a patient who had episodes of severe hypoglycemia in 1927 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/2\">",
"     2",
"    </a>",
"    ]. Extracts of the tumor caused marked hypoglycemia in rabbits. The first cure of hyperinsulinism by removal of an insulinoma was reported in 1929 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of insulinomas will be reviewed here. The causes and evaluation of hypoglycemia, and the management of metastatic neuroendocrine tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common clinical manifestation of an insulinoma is fasting hypoglycemia, with discrete episodes of neuroglycopenic symptoms that may or may not be preceded by sympathoadrenal (autonomic) symptoms. However, postprandial hypoglycemia may be a feature or even the sole manifestation of hypoglycemia in some patients. In a retrospective review of 237 patients with surgically confirmed insulinoma, managed over the period 1987 to 2007, 21 percent reported both fasting and postprandial symptoms and 6 percent reported only postprandial symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"     4",
"    </a>",
"    ]. The hypoglycemia in persons with insulinoma is primarily due to reduced hepatic glucose output rather than increased glucose utilization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=see_link\">",
"     \"Hypoglycemia in adults: Clinical manifestations, definition, and causes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=see_link\">",
"     \"Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evidence suggests that insulinomas arise from cells of the",
"    <span class=\"nowrap\">",
"     ductular/acinar",
"    </span>",
"    system of the pancreas rather than from neoplastic proliferation of islet cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/6\">",
"     6",
"    </a>",
"    ]. The mechanism by which insulinomas maintain high levels of insulin secretion in the presence of hypoglycemia is unknown. However, one study reported that a variant of insulin mRNA with increased translation efficiency is present in high amounts in insulinomas when compared with normal islets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41702?source=see_link\">",
"     \"Insulin secretion and pancreatic beta-cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;During a six-decade period of observation (1927 to 1986), there were eight cases of insulinoma in residents of Olmsted County, Minnesota, indicating an incidence of 0.4 per 100,000 person-years (or four cases per million per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"     8",
"    </a>",
"    ]. The distributions by age and gender in a subsequent (1987 to 2007) series from the same institution were similar to those of the earlier cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"     4",
"    </a>",
"    ]. Insulinomas have been observed in all ethnic groups.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mayo Clinic series",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulinomas are so rare that few institutions have accrued enough experience to provide meaningful data regarding their demographic characteristics. This discussion will highlight the demographic and incidence data from the relatively large number of patients with insulinomas at the Mayo Clinic and the comprehensive database for residents of Olmsted County (where the Mayo Clinic is located) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4,8,9\">",
"     4,8,9",
"    </a>",
"    ]. The most recent cohort was seen over a 20-year period from 1987 to 2007 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"     4",
"    </a>",
"    ]. Each patient had an insulinoma removed at his or her first pancreatic exploration, which took place at the Mayo Clinic. Patients with insulinoma and a prior history of gastric bypass were excluded. The demographic features reported from other centers have usually been similar [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Distribution of cases by age and sex",
"    </span>",
"    &nbsp;&mdash;&nbsp;For the series observed from 1987 to 2007, there were 237 patients, the median age (and range) at the time of surgery was 50 years (range 17 to 86), and 57 percent were women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"     4",
"    </a>",
"    ]. There were no demographic differences between this series and that reported for the period 1927 to 1986 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neuroglycopenic symptoms of insulinoma included confusion, visual change, and unusual behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/9\">",
"     9",
"    </a>",
"    ]. Sympathoadrenal symptoms may include palpitations, diaphoresis, and tremulousness [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/12\">",
"     12",
"    </a>",
"    ]. Amnesia for hypoglycemia is common.",
"   </p>",
"   <p>",
"    The median duration of symptoms before diagnosis was less than 1.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"     8",
"    </a>",
"    ]. However, a few patients had probably been symptomatic for decades. As many as 20 percent of patients had been misdiagnosed with a neurologic or psychiatric disorder before the insulinoma was recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/9,13\">",
"     9,13",
"    </a>",
"    ]. Seizure disorder is another common misdiagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8,12\">",
"     8,12",
"    </a>",
"    ]. Weight gain was described in 18 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, symptoms of hypoglycemia occurred exclusively in the fasting state in 73 percent, whereas 21 percent reported both fasting and postprandial symptoms and 6 percent reported only postprandial symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"     4",
"    </a>",
"    ]. During the period of study, there was an increase in the frequency of reporting only postprandial symptoms (2 percent from 1987 to 1992 compared with 10 percent from 2003 to 2007).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     MEN1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the 237 patients in one cohort, 14 (6 percent) had multiple endocrine neoplasia (MEN) type 1, of whom 71 percent were men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"     4",
"    </a>",
"    ]. Thirteen (93 percent) had benign insulinomas. Twelve (86 percent) had multiple islet tumors, as compared with only 3 percent in the rest of the cohort. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tumor distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulinomas can be single or multiple, and benign or malignant. Among the 224 patients in one cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      194 (87 percent) had single benign tumors (one being ectopic)",
"     </li>",
"     <li>",
"      16 (7 percent) had multiple benign tumors",
"     </li>",
"     <li>",
"      13 (6 percent) had malignant insulinomas, defined as the presence of metastases",
"     </li>",
"     <li>",
"      One had islet hyperplasia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The median age (and range) of patients with malignant insulinoma was 48 years (18 to 61), and 77 percent were men.",
"   </p>",
"   <p>",
"    Patients who required additional surgical treatment because of failed initial surgery or recurrence of insulinoma over the period 1927 to 1986 had an increased prevalence of MEN 1 with multiple tumors (25 percent) and malignant insulinomas (13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Insulinomas have been reported in pregnant women, patients with type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/15,16\">",
"     15,16",
"    </a>",
"    ], in one patient with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/14\">",
"     14",
"    </a>",
"    ], and in one patient with renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of insulinoma is established by demonstrating inappropriately high serum insulin concentrations during a spontaneous or induced episode of hypoglycemia, eg, 72-hour fast for a patient with fasting hypoglycemia, or in the case of the patient with solely postprandial symptoms, the mixed meal test. Virtually all insulinomas are islet-cell tumors; there is one report of an insulin-secreting small cell carcinoma of the cervix [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/18\">",
"     18",
"    </a>",
"    ]. Other tumors can produce hypoglycemia by different mechanisms, such as the production of insulin-like growth factor-II. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic endocrine tumors such as insulinomas are included in the combined American Joint Committee on Cancer",
"    <span class=\"nowrap\">",
"     (AJCC)/International",
"    </span>",
"    Union Against Cancer (UICC) TNM (tumor-node-metastasis) staging system for pancreatic tumors (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/19\">",
"     19",
"    </a>",
"    ]. Five and 10-year survival rates for patients undergoing resection on pancreatic neuroendocrine tumors (both islet cell and carcinoid tumors) stratified by stage at presentation are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef80523 \" href=\"UTD.htm?4/42/4780\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Malignant potential",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant insulinomas are rare and, therefore, there are few data regarding their clinical presentation and long-term prognosis. They are generally indolent tumors, and some patients have prolonged survival, even in the presence of liver or lymph node metastases. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Patient survival'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biologic behavior of pancreatic endocrine tumors does not always correspond to their histologic characteristics; even malignant tumors show little or no cellular pleomorphism, hyperchromasia, or increased mitotic activity. Thus, staging and grading systems have been developed to better study and predict long-term outcomes. As an example, the World Health Organization estimates the malignant potential of gastroenteropancreatic neuroendocrine tumors using a classification scheme that is based upon stage-related (ie, tumor size &lt;2 versus &gt;2 cm, and the presence of metastases) and grade-related (mitotic rate, perineural and lymphovascular invasion, Ki-67 proliferative index) criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/21\">",
"     21",
"    </a>",
"    ]. Another classification scheme estimates malignant potential using similar staging criteria but a simplified grading system (mitotic rate and presence of necrosis) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are other disorders in which the biochemical findings simulate those of an insulinoma because they are also associated with primary overproduction of insulin: familial persistent hyperinsulinemic hypoglycemia of infancy, primary islet-cell hyperplasia (also called nesidioblastosis), noninsulinoma pancreatogenous hypoglycemia syndrome, and post-gastric bypass hypoglycemia. The latter two conditions have the characteristic feature of producing primarily postprandial hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44614?source=see_link\">",
"     \"Noninsulinoma pancreatogenous hypoglycemia syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TUMOR LOCALIZATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Noninvasive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;After diagnosis, imaging techniques are then used to localize the tumor. Accurate preoperative localization of an insulinoma is desirable because some tumors may not be palpable at the time of surgery, and patients can be advised of the type of surgery planned [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/23\">",
"     23",
"    </a>",
"    ]. The noninvasive procedures available include spiral CT, MRI, transabdominal ultrasonography, 111-In-pentetreotide imaging, and fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-DOPA PET) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. The choice of procedure depends upon which tests are available and local radiologic skill. Transabdominal ultrasonography is our preferred initial test. In a series of 237 patients with insulinoma who were evaluated at the Mayo Clinic, the rate of detection by transabdominal ultrasound and triple-phase spiral CT of the pancreas was approximately 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pentetreotide scintigraphy will miss up to 40 percent of insulinomas because these tumors do not express a sufficient number of subtype 2 somatostatin receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/24,26\">",
"     24,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=see_link\">",
"     \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many insulinomas have high concentrations of glucagon-like peptide-1 (GLP-1) receptors. GLP-1 radioligands that bind to the GLP-1 receptor have been developed. In a small series, GLP-1 receptor scintigraphy successfully localized insulinoma in six patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/27\">",
"     27",
"    </a>",
"    ]. This modality requires further investigation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Invasive tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with endogenous hyperinsulinemic hypoglycemia and negative noninvasive radiologic localization studies, endoscopic ultrasonography or a selective arterial calcium stimulation test (SACST) with hepatic venous sampling can be performed to localize the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Overall, with appropriate preoperative localization studies plus intraoperative ultrasonography and palpation, a tumor (or tumors) can be identified in 98 percent of patients with insulinomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Endoscopic ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;In small case series, the sensitivity of endoscopic ultrasound for the detection of insulinoma confirmed by surgery but not detected by transabdominal ultrasonography or CT ranged from 82 to 85 percent (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef74947 \" href=\"UTD.htm?13/61/14288\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. In the larger series (237 patients) from the Mayo Clinic, the sensitivity of endoscopic ultrasound for localization of insulinoma was 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Selective arterial calcium stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantage of SACS is that it is also a dynamic test. Arterial calcium stimulation with hepatic venous sampling involves selective injection of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/11/18616?source=see_link\">",
"     calcium gluconate",
"    </a>",
"    into the gastroduodenal, splenic, and superior mesenteric arteries with subsequent sampling of the hepatic venous effluent for insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. This test is based upon the observation that calcium stimulates the release of insulin from hyperfunctional beta cells (insulinomas or nesidioblastosis), but not normal beta cells. Calcium stimulates insulin release in the same arterial territory as the abnormal beta cells, which facilitates operative localization.",
"   </p>",
"   <p>",
"    In the Mayo Clinic series, the sensitivity of SACS for localization of insulinoma was 93 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"     4",
"    </a>",
"    ]. When invasive testing (endoscopic ultrasound",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    SACS) was performed in patients with negative noninvasive (ultrasound, CT abdomen) testing, tumor localization was achieved in all cases from 1998 onward. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link&amp;anchor=H24#H24\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\", section on 'Arterial calcium stimulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Initial surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical removal of the insulinoma is the treatment of choice. The following procedures were performed in the Mayo Clinic cohort [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Enucleation of the insulinoma &mdash; 130 patients",
"     </li>",
"     <li>",
"      Partial distal pancreatectomy &mdash; 73 patients",
"     </li>",
"     <li>",
"      Enucleation of the insulinoma and partial pancreatectomy &mdash; nine patients",
"     </li>",
"     <li>",
"      A Whipple procedure (removal of the head of the pancreas, gastrectomy, duodenectomy, and splenectomy) &mdash; one patient",
"     </li>",
"     <li>",
"      Total pancreatectomy &mdash; one patient",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The surgical procedure was chosen by the surgeon, and none of the operations in the series (1927 to 1986) were done via the laparoscope. Since then, a few cases have been managed laparoscopically. The rate of surgical complications was approximately 10 percent.",
"   </p>",
"   <p>",
"    In addition, eight patients with malignant insulinomas underwent biopsy of metastatic lesions, and the tumor was found at autopsy after perioperative death in one patient. Histologic examination of this tumor revealed a malignant islet cell tumor that stained intensively for insulin (",
"    <a class=\"graphic graphic_picture graphicRef68737 graphicRef56940 \" href=\"UTD.htm?32/63/33786\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1927 to 1986 series, the following results were noted after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      196 patients were cured, as defined by being totally free of symptoms for at least six months after removal of the insulinoma",
"     </li>",
"     <li>",
"      19 patients (10 with benign insulinomas, eight with malignant insulinomas, and one with islet-cell hyperplasia) had persistent hypoglycemia",
"     </li>",
"     <li>",
"      Five developed diabetes mellitus",
"     </li>",
"     <li>",
"      Four died perioperatively; all four were operated on before 1941",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among the 10 patients who had benign insulinomas and persistent hypoglycemia after initial surgical treatment, six had multiple tumors (four due to MEN 1). Five of these six patients underwent reoperation. Three of the five were found to have additional multiple tumors; one was cured and two developed diabetes mellitus after the second operation. Two patients with single tumors at initial operation had persistent hypoglycemia after the second operation because additional insulinomas were not identified.",
"   </p>",
"   <p>",
"    For patients with insulinoma related to MEN1, some experienced surgeons recommend local excision of any tumors found in the head of the pancreas plus a distal subtotal pancreatectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/31\">",
"     31",
"    </a>",
"    ]. This approach differs from that in patients with sporadic insulinomas, who typically have a solitary tumor and in whom enucleation is usually successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laparoscopic surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some centers, laparoscopic pancreatic surgery is sometimes performed for small, solitary insulinomas that have been localized preoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Intraoperative laparoscopic ultrasound may help minimize the need for conversion to open pancreatic surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Evaluation for missed insulinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reoperation for missed insulinoma presents unique problems. First, the diagnosis must be confirmed. Second, one or more localizing procedures should be done. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Tumor localization'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Reoperation for insulinoma should only be performed by a surgeon experienced with this situation and accompanied by highly experienced endocrinologic and radiologic support. Blind pancreatic resection should not be performed if a tumor is not identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Risk of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, 196 patients in the 1927 to 1986 series were in remission soon after surgery (defined as a six-month period free of symptoms after initial removal of an insulinoma). Among these patients, 11 (6 percent) had recurrent hypoglycemia. Eight of these patients underwent repeat exploration of the pancreas: six had pathologic confirmation of recurrent insulinoma, one had persistent hypoglycemia despite total pancreatectomy, and one died intraoperatively. Pancreatic reexploration was not performed in the other three patients because of age and concerns about diabetes. Recurrence of hypoglycemia within four years of the successful removal of an insulinoma suggests regrowth of residual insulinoma tissue left behind as a result of fracturing of the original tumor. In this case, the tumor is at the same site as the original tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recurrences occurred from 4 to 18.5 years after the initial operation. The cumulative incidence of recurrence was 6 percent at 10 years and 8 percent at 20 years. Recurrences were more common in the patients with MEN 1; the cumulative 10- and 20-year recurrence rates were 21 percent at both times compared with 5 and 7 percent in those without MEN 1 (p&lt;0.001)&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef82017 \" href=\"UTD.htm?6/7/6270\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"     8",
"    </a>",
"    ]. Among four patients with malignant insulinoma who were symptom-free for six or more months after the initial operation, two patients had recurrences at four and nine years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Patient survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall survival rate of patients with insulinoma did not differ from that expected in the general population. Survival, however, was significantly worse in the patients with malignant insulinomas (but better than in patients with acinar pancreatic carcinoma), in older patients, and in those diagnosed early in the period of observation (1927 through 1986)&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef67328 \" href=\"UTD.htm?42/49/43805\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients with malignant insulinoma appear to have a prolonged natural history. In a series of 10 patients treated at the National Institutes of Health over a 20-year period for metastatic insulinoma, nine remained alive long-term (up to 25 years), three with liver metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/36\">",
"     36",
"    </a>",
"    ]. Four had developed metastatic disease from 4 to 12 years after initial diagnosis, while four had resected lymph node metastases as the only site of disease. Various treatment modalities were used to control hypoglycemia. In this series, short-term benefits were most often achieved with embolization and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"     diazoxide",
"    </a>",
"    , and less often with radiofrequency ablation, radical debulking surgery,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    , and chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Medical therapy to control symptomatic hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical therapy should be considered in the patient whose insulinoma was missed during pancreatic exploration, who is not a candidate for or refuses surgery, or who has unresectable metastatic disease. The therapeutic choices to prevent symptomatic hypoglycemia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"       Diazoxide",
"      </a>",
"      (which diminishes insulin secretion and is given in divided doses of up to 1200",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      is sometimes used for controlling hypoglycemia [",
"      <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/36-38\">",
"       36-38",
"      </a>",
"      ]. However, it can cause marked edema (which may require high doses of loop diuretics) and hirsutism.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       Octreotide",
"      </a>",
"      , an analog of somatostatin (growth hormone-inhibitory hormone), inhibits GH secretion, but in large doses also inhibits the secretion of TSH, insulin, and glucagon. While octreotide is highly effective in controlling the symptoms associated with glucagonomas, VIPomas, and carcinoid tumors, efficacy is less predictable for symptomatic patients with insulinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/36,39-42\">",
"       36,39-42",
"      </a>",
"      ]. Nevertheless, it is a reasonable choice for patients with persistent hypoglycemia that is refractory to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"       diazoxide",
"      </a>",
"      .",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/34/7717?source=see_link\">",
"       Lanreotide",
"      </a>",
"      , another somatostatin analog that is available internationally and in the US for the treatment of acromegaly, appears to have similar clinical efficacy as octreotide, and is also available in a long-acting depot form (Lanreotide-SR). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948928#H190948928\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Octreotide and other somatostatin analogs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/36\">",
"       36",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/43\">",
"       43",
"      </a>",
"      ] have also been used with some success. However, none of these drugs is as effective as tumor resection.",
"     </li>",
"     <li>",
"      Although experience is limited, at least some data suggest that refractory cases may respond to treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      , an inhibitor of the mammalian target of rapamycin (mTOR). This drug is not yet available in the US. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949061#H190949061\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'mTOR inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with external beam radiotherapy (RT) in the management of islet cell tumors is limited. Although pancreatic neuroendocrine carcinomas were previously considered to be radioresistant, data from published case reports and small case series suggest that RT can produce high rates of symptom palliation and freedom from local progression in patients who are not candidates for surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. There are no data specifically on the rate of symptom control in patients with symptomatic insulinomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Liver-directed therapy for metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The liver and regional lymph nodes are the most common sites of metastatic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic resection is indicated for the treatment of metastatic liver disease in the absence of diffuse bilobar involvement, compromised liver function, or extensive extrahepatic metastases (eg, pulmonary, peritoneal). Although the majority of cases will not be cured by surgery, prolonged survival is often possible, given the slow-growing nature of these tumors.",
"   </p>",
"   <p>",
"    In general, resection should be considered only for patients with a limited number of hepatic metastases and is most successful when undertaken with curative intent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Hepatic artery embolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver metastases derive most of their blood supply from the hepatic artery, whereas healthy hepatocytes derive most of their blood supply from the portal vein. This provides the rationale for therapeutic embolization of the hepatic artery, with the goal of inducing necrosis of the metastases with minimal damage to normal liver parenchyma.",
"   </p>",
"   <p>",
"    Hepatic arterial embolization with or without selective hepatic artery infusion of chemotherapy is frequently applied as a palliative technique in patients with symptomatic hepatic metastases who are not candidates for surgical resection. Response rates, as measured by a decrease in hormonal secretion or by radiographic regression, are generally over 50 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     RFA and cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other approaches to the treatment of hepatic-predominant disease include radiofrequency ablation (RFA) and cryoablation, either alone or in conjunction with surgical debulking. These procedures, which can be performed using percutaneous or laparoscopic approaches, appear to be less morbid than either hepatic resection or hepatic artery embolization. However, both techniques are applicable only to smaller lesions, and their long-term efficacy is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691456#H691456\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'RFA and cryoablation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14740621\">",
"    <span class=\"h3\">",
"     Radioembolization",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative means of delivering focal RT uses radioactive isotopes (eg, yttrium-90 [90-Y]) that are tagged to glass or resin microspheres, and delivered selectively to the tumor via the hepatic artery. Evidence of benefit is limited. In one case report, radioembolization improved refractory hypoglycemia for three months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Liver transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of patients with liver-isolated metastatic disease in whom orthotopic liver transplantation (OLT) has been attempted is small, and follow-up data are insufficient to judge whether complete cure has truly been achieved. The limited availability of donor organs in many regions has restricted investigation of this procedure. Until more data become available, most clinicians consider that liver transplantation is an investigational approach for metastatic islet cell tumors, including insulinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link&amp;anchor=H691420#H691420\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Liver transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Chemotherapy and novel treatment approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with systemic chemotherapy is limited. The traditional regimen of choice has been",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    . Although objective response rates as high as 69 percent were initially reported for metastatic islet cell tumors, the true radiologic response rate is probably lower, between 10 and 40 percent. Uncertainty as to efficacy, as well as the toxicity of this regimen (nausea, prolonged myelosuppression, renal failure), has prevented its widespread acceptance as a standard first-line therapy.",
"   </p>",
"   <p>",
"    Antitumor activity has also been shown for regimens containing the orally active alkylating agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    . In the absence of comparative trials, the choice of first-line",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?9/30/9702?source=see_link\">",
"      streptozocin",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"      doxorubicin",
"     </a>",
"    </span>",
"    or a temozolomide-based regimen must be individualized, taking into account the convenience of oral rather than intravenous treatment, performance status, and the anticipated side effect profile of both combinations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190948956#H190948956\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Cytotoxic chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The modest efficacy of conventional cytotoxic chemotherapy has prompted the development of novel therapeutic approaches for patients with advanced islet cell tumors. These include molecularly targeted therapy with small molecule tyrosine kinase inhibitors, and inhibitors of the mammalian target of rapamycin (mTOR), as well as peptide receptor radioligand therapy. These topics are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949026#H190949026\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Molecularly targeted therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949119#H190949119\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Peptide receptor radioligand therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no evidence-based guidelines for follow-up after resection of a malignant insulinoma. Consensus-derived guidelines from the National Comprehensive Cancer Network following treatment for an islet cell tumor include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12777/abstract/49\">",
"     49",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three and six months postresection &mdash; History and physical examination, tumor markers, and",
"      <span class=\"nowrap\">",
"       CT/MRI.",
"      </span>",
"     </li>",
"     <li>",
"      Long-term &mdash; History and physical examination with tumor markers every 6 to 12 months for years one to three, and as clinically indicated thereafter. Imaging studies are recommended only as clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/51/18226?source=see_link\">",
"       \"Patient information: Low blood sugar in people without diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Insulinomas are rare pancreatic islet cell tumors not limited to any ethnic group (incidence of 1 case per 250,000 person-years); while most are sporadic, some are associated with the MEN1 syndrome. The characteristic clinical manifestation of an insulinoma is fasting hypoglycemia, (although some patients also have postprandial hypoglycemia), with neuroglycopenic symptoms which may or may not be preceded by sympathoadrenal (autonomic) symptoms. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Most insulinomas are solitary and benign. Multiple insulinomas are less common, and tend to be associated with MEN1. Malignant insulinomas are also less common. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Tumor distribution'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of insulinoma is established by demonstrating inappropriately high serum insulin concentrations during a spontaneous or induced episode of hypoglycemia (eg, 72-hour fast for fasting hypoglycemia or a mixed meal test for postprandial hypoglycemia). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=see_link\">",
"     \"Hypoglycemia in adults without diabetes mellitus: Diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging techniques are then used to localize the tumor. Accurate preoperative localization of an insulinoma is desirable. Transabdominal ultrasonography and CT are our preferred initial test, followed by endoscopic ultrasonography or arterial stimulation with hepatic venous sampling when an insulinoma has not been localized by noninvasive techniques. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Diagnosis and staging'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Tumor localization'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For initial therapy of patients with benign, solitary insulinomas, we recommend surgical excision of the tumor (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The approach and extent of surgery should be determined based upon tumor location. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Initial surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with multiple insulinomas (typically in the setting of MEN1), we suggest local excision of any tumors found in the head of the pancreas plus a distal subtotal pancreatectomy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Initial surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with persistent hypoglycemia after surgery in whom solitary or multiple tumors are identified after additional localization procedures, we recommend repeat operation (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Initial surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients whose insulinoma cannot be located during pancreatic exploration, who are not candidates for or refuse surgery, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"       diazoxide",
"      </a>",
"      therapy for the medical management of hypoglycemia (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Medical therapy to control symptomatic hypoglycemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with potentially resectable liver-isolated metastatic insulinoma, we recommend surgical resection of the hepatic metastases along with the primary tumor (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Although the majority of cases will not be cured by surgery, given the slow-growing nature of the tumor, extended survival is sometimes possible. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other treatment options for patients with unresectable hepatic-predominant symptomatic metastatic disease include embolization, chemoembolization, RFA, and cryoablation. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Liver-directed therapy for metastatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The efficacy of somatostatin analogs for patients with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/38/13924?source=see_link\">",
"       diazoxide",
"      </a>",
"      -refractory symptomatic hypoglycemia is unpredictable, but some patients may benefit.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/7/43128?source=see_link\">",
"       Octreotide",
"      </a>",
"      , as well as other systemic therapy approaches (interferon, chemotherapy, targeted radiotherapy) are discussed in detail elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/1\">",
"      Harris, S. Hyperinsulinism and dysinsulinism. JAMA 1924; 83:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/2\">",
"      Wilder, RM, Allan, FN, Power, MH, et al. Carcinoma of the islands of the pancreas. JAMA 1927; 89:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/3\">",
"      Howland, G, Campbell, WR, Malthby, EJ, et al. Dysinsulinism: Convulsions and coma due to islet cell tumor of pancreas, with operation and cure. JAMA 1929; 93:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/4\">",
"      Placzkowski KA, Vella A, Thompson GB, et al. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab 2009; 94:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/5\">",
"      Rizza RA, Haymond MW, Verdonk CA, et al. Pathogenesis of hypoglycemia in insulinoma patients: suppression of hepatic glucose production by insulin. Diabetes 1981; 30:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/6\">",
"      Vortmeyer AO, Huang S, Lubensky I, Zhuang Z. Non-islet origin of pancreatic islet cell tumors. J Clin Endocrinol Metab 2004; 89:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/7\">",
"      Minn AH, Kayton M, Lorang D, et al. Insulinomas and expression of an insulin splice variant. Lancet 2004; 363:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/8\">",
"      Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 1991; 66:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/9\">",
"      Service FJ, Dale AJ, Elveback LR, Jiang NS. Insulinoma: clinical and diagnostic features of 60 consecutive cases. Mayo Clin Proc 1976; 51:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/10\">",
"      Kavlie H, White TT. Pancreatic islet beta cell tumors and hyperplasia: experience in 14 Seattle hospitals. Ann Surg 1972; 175:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/11\">",
"      Cullen RM, Ong CE. Insulinoma in Auckland 1970-1985. N Z Med J 1987; 100:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/12\">",
"      Dizon AM, Kowalyk S, Hoogwerf BJ. Neuroglycopenic and other symptoms in patients with insulinomas. Am J Med 1999; 106:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/13\">",
"      Harrington MG, McGeorge AP, Ballantyne JP, Beastall G. A prospective survey for insulinomas in a neurology department. Lancet 1983; 1:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/14\">",
"      Brennan MD, Service FJ, Carpenter AM, et al. Diagnosis of pancreatic islet hyperplasia causing hypoglycemia in a patient with portacaval anastomosis. Am J Med 1980; 68:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/15\">",
"      Kane LA, Grant CS, Nippoldt TB, Service FJ. Insulinoma in a patient with NIDDM. Diabetes Care 1993; 16:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/16\">",
"      Svartberg J, Stridsberg M, Wilander E, et al. Tumour-induced hypoglycaemia in a patient with insulin-dependent diabetes mellitus. J Intern Med 1996; 239:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/17\">",
"      Basu A, Sheehan MT, Thompson GB, Service FJ. Insulinoma in chronic renal failure: a case report. J Clin Endocrinol Metab 2002; 87:4889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/18\">",
"      Seckl MJ, Mulholland PJ, Bishop AE, et al. Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix. N Engl J Med 1999; 341:733.",
"     </a>",
"    </li>",
"    <li>",
"     AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York  Vol 2010, p.241.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/20\">",
"      Bilimoria KY, Bentrem DJ, Merkow RP, et al. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/21\">",
"      Kl&ouml;ppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/22\">",
"      Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 2007; 25:5609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/23\">",
"      Fedorak IJ, Ko TC, Gordon D, et al. Localization of islet cell tumors of the pancreas: a review of current techniques. Surgery 1993; 113:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/24\">",
"      Modlin IM, Tang LH. Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today). Gastroenterology 1997; 112:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/25\">",
"      Kauhanen S, Sepp&auml;nen M, Minn H, et al. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab 2007; 92:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/26\">",
"      Miralli&eacute; E, Pattou F, Malvaux P, et al. [Value of endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localization of insulinomas and gastrinomas. Experience of 54 cases]. Gastroenterol Clin Biol 2002; 26:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/27\">",
"      Christ E, Wild D, Forrer F, et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 2009; 94:4398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/28\">",
"      R&ouml;sch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992; 326:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/29\">",
"      Doppman JL, Miller DL, Chang R, et al. Insulinomas: localization with selective intraarterial injection of calcium. Radiology 1991; 178:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/30\">",
"      Pereira PL, Roche AJ, Maier GW, et al. Insulinoma and islet cell hyperplasia: value of the calcium intraarterial stimulation test when findings of other preoperative studies are negative. Radiology 1998; 206:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/31\">",
"      Demeure MJ, Klonoff DC, Karam JH, et al. Insulinomas associated with multiple endocrine neoplasia type I: the need for a different surgical approach. Surgery 1991; 110:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/32\">",
"      Assalia A, Gagner M. Laparoscopic pancreatic surgery for islet cell tumors of the pancreas. World J Surg 2004; 28:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/33\">",
"      Ayav A, Bresler L, Brunaud L, et al. Laparoscopic approach for solitary insulinoma: a multicentre study. Langenbecks Arch Surg 2005; 390:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/34\">",
"      Thompson GB, Service FJ, van Heerden JA, et al. Reoperative insulinomas, 1927 to 1992: an institutional experience. Surgery 1993; 114:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/35\">",
"      Service FJ. Recurrent hyperinsulinemic hypoglycemia caused by an insulin-secreting insulinoma. Nat Clin Pract Endocrinol Metab 2006; 2:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/36\">",
"      Hirshberg B, Cochran C, Skarulis MC, et al. Malignant insulinoma: spectrum of unusual clinical features. Cancer 2005; 104:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/37\">",
"      Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 1997; 73:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/38\">",
"      Goode PN, Farndon JR, Anderson J, et al. Diazoxide in the management of patients with insulinoma. World J Surg 1986; 10:586.",
"     </a>",
"    </li>",
"    <li>",
"     Service FJ. Hypoglycemia including hypoglycemia in neonates and children. In: Endocrinology, 3rd, DeGroot LJ (Ed), WB Saunders, Philadelphia 1995. p.160.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/40\">",
"      Romeo S, Milione M, Gatti A, et al. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res 2006; 65:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/41\">",
"      Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/42\">",
"      Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/43\">",
"      Hofeldt FD, Dippe SE, Levin SR, et al. Effects of diphenylhydantoin upon glucose-induced insulin secretion in three patients with insulinoma. Diabetes 1974; 23:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/44\">",
"      Contessa JN, Griffith KA, Wolff E, et al. Radiotherapy for pancreatic neuroendocrine tumors. Int J Radiat Oncol Biol Phys 2009; 75:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/45\">",
"      Strosberg J, Hoffe S, Gardner N, et al. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology 2007; 85:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/46\">",
"      Tennvall J, Ljungberg O, Ahr&eacute;n B, et al. Radiotherapy for unresectable endocrine pancreatic carcinomas. Eur J Surg Oncol 1992; 18:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/47\">",
"      Torrisi JR, Treat J, Zeman R, Dritschilo A. Radiotherapy in the management of pancreatic islet cell tumors. Cancer 1987; 60:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12777/abstract/48\">",
"      Chandra P, Yarandi SS, Khazai N, et al. Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma. Am J Med Sci 2010; 340:414.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2187 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12777=[""].join("\n");
var outline_f12_30_12777=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mayo Clinic series",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Distribution of cases by age and sex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - MEN1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tumor distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS AND STAGING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Malignant potential",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TUMOR LOCALIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Noninvasive tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Invasive tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Endoscopic ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Selective arterial calcium stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Initial surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Outcome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Evaluation for missed insulinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Risk of recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Patient survival",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Medical therapy to control symptomatic hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Liver-directed therapy for metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Hepatic artery embolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - RFA and cryoablation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14740621\">",
"      - Radioembolization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Chemotherapy and novel treatment approaches",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2187\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2187|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?13/61/14288\" title=\"diagnostic image 1\">",
"      EUS insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2187|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/7/6270\" title=\"figure 1\">",
"      Recurrence of insulinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/49/43805\" title=\"figure 2\">",
"      Survival with insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2187|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/23/378\" title=\"picture 1A\">",
"      Insulinoma Light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/57/22419\" title=\"picture 1B\">",
"      Insulinoma insulin stain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2187|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/32/43532\" title=\"table 1\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/42/4780\" title=\"table 2\">",
"      Survival rates following resection of a pancreatic neuroendocrine tumor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24184?source=related_link\">",
"      Hypoglycemia in adults without diabetes mellitus: Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/39/44664?source=related_link\">",
"      Hypoglycemia in adults: Clinical manifestations, definition, and causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41702?source=related_link\">",
"      Insulin secretion and pancreatic beta-cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/14/43240?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/36/44614?source=related_link\">",
"      Noninsulinoma pancreatogenous hypoglycemia syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/51/18226?source=related_link\">",
"      Patient information: Low blood sugar in people without diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29638?source=related_link\">",
"      Physiologic response to hypoglycemia in normal subjects and patients with diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_30_12778="Bacterial infections following lung transplantation";
var content_f12_30_12778=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bacterial infections following lung transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12778/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12778/contributors\">",
"     Aimee Zaas, MD, MHS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12778/contributors\">",
"     David W Zaas, MD, MBA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12778/contributors\">",
"     Scott M Palmer, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12778/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12778/contributors\">",
"     Elbert P Trulock, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12778/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/30/12778/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/30/12778/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/30/12778/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplantation is an effective treatment for a wide range of advanced lung diseases. While the survival of lung transplant recipients continues to improve, outcomes after lung transplantation remain inferior to other types of solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Infectious complications contribute substantially to morbidity and mortality following lung transplantation and account for over 25 percent of all post-transplant deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the most common bacterial infections in lung transplant recipients. Infections caused by fungi, mycobacteria, and viruses in lung transplant recipients and general issues regarding infections in solid organ transplant recipients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RISK OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplant recipients are at increased risk for infectious complications due to the following factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The high level of immunosuppression required to prevent rejection",
"     </li>",
"     <li>",
"      Adverse effects of transplantation on local pulmonary host defenses (loss of lymphatics, reduced mucociliary clearance, decreased cough)",
"     </li>",
"     <li>",
"      Constant environmental contact allowing pathogens direct access into the allograft",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood and type of infection varies with the degree of host immunosuppression, timing since transplantation, nature and duration of antimicrobial prophylaxis, and local hospital and regional microbiology (",
"    <a class=\"graphic graphic_table graphicRef54898 \" href=\"UTD.htm?17/59/18365\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pneumonia, particularly bacterial pneumonia, is the most common type of infection in lung transplant recipients, although bloodstream, pleural space, and wound infections are also common [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Bacterial, viral, fungal, and mycobacterial infections all occur at an increased frequency after lung transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the direct morbidity and mortality caused by infectious complications, they may also lead to loss of allograft function and contribute to the development of bronchiolitis obliterans syndrome (BOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=see_link\">",
"     \"Chronic lung transplant rejection: Bronchiolitis obliterans\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022150\">",
"    <span class=\"h1\">",
"     TIMELINE OF INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections generally occur in a predictable pattern following solid organ transplantation. The post-transplant period has been divided into three stages: the first month post-transplant, one to six months post-transplant, and more than six months post-transplant.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During the early post-transplant period, bacterial infections predominate. During the first month, there are two major causes of infection:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infection derived from either the donor or recipient, and",
"     </li>",
"     <li>",
"      Infectious complications of the transplant surgery and hospitalization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      From one to six months post-transplant, patients are most at risk for opportunistic infections, although residual problems from the perioperative period can persist.",
"     </li>",
"     <li>",
"      More than six months post-transplant, most patients are receiving stable and reduced levels of immunosuppression. These patients are subject to pneumonia caused by an extended range of bacteria, including pneumococcus, gram-negative bacilli, Legionella, and other common pathogens, rather than opportunistic infections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pattern of infection seen during these periods is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link&amp;anchor=H15#H15\">",
"     \"Infection in the solid organ transplant recipient\", section on 'Timing of infection posttransplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EVALUATION FOR INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for infection in lung transplant recipients should follow the general approach used in all solid organ transplant recipients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link&amp;anchor=H26#H26\">",
"     \"Infection in the solid organ transplant recipient\", section on 'Evaluation and management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several unique considerations apply to lung transplant recipients in whom pneumonia is the most common type of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/3\">",
"     3",
"    </a>",
"    ]. Some lung transplant recipients with pneumonia present with fever, cough, dyspnea, and infiltrates on chest imaging. However, some patients have few or atypical symptoms due to the blunting of the immune response by immunosuppressive drugs. In addition, the presentation of infection often overlaps with that of allograft rejection; thus, a high index of suspicion for both infection and rejection should be maintained to ensure early appropriate diagnosis and therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=see_link\">",
"     \"Evaluation and treatment of acute lung transplant rejection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022190\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since pneumonia is the most common type of infection in lung transplant recipients, the diagnostic evaluation generally includes early and aggressive evaluation of the lungs as a potential source. Lung transplant recipients can deteriorate quickly in the absence of appropriate therapy. Thus, a reasonable approach to the lung transplant patient with respiratory symptoms involves initial empiric treatment for infection while awaiting microbiologic and histopathologic data. The specific organisms targeted by the empiric regimen depend upon the patient's risk factors and clinical presentation. (See",
"    <a class=\"local\" href=\"#H1627022723\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    After initiation of empiric antimicrobial therapy and imaging with a chest radiograph, invasive diagnostic testing should be considered in most lung transplant recipients unless contraindications exist. In addition, chest CT may be helpful in patients when a pulmonary infection is uncertain based on clinical history, exam, and chest radiographs alone.",
"   </p>",
"   <p>",
"    Bronchoscopy with bronchoalveolar lavage (BAL) is the most sensitive diagnostic study to identify the etiology of pulmonary infections and rule out atypical etiologies. Due to the similar clinical presentation, we normally perform transbronchial biopsies at the same time to rule out rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, it is possible that infection and rejection may coexist.",
"   </p>",
"   <p>",
"    The table summarizes appropriate microbiological studies of the BAL fluid (",
"    <a class=\"graphic graphic_table graphicRef70685 \" href=\"UTD.htm?28/8/28813\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022209\">",
"    <span class=\"h1\">",
"     BACTERIAL INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial infection is the most common early infectious complication after lung transplantation and remains a leading cause of death throughout the post-transplant period [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/7\">",
"     7",
"    </a>",
"    ]. In addition to pneumonia, lung transplant recipients are at risk for other types of bacterial infections including empyema, bloodstream infection, and wound infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022221\">",
"    <span class=\"h2\">",
"     Sites of infection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022228\">",
"    <span class=\"h3\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk for the development of bacterial pneumonia is influenced by both donor and recipient factors, and the risk is highest during the early post-transplant period. Despite antibiotic prophylaxis, the incidence of bacterial pneumonia is approximately 10 to 20 percent in the first 30 days post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In a prospective multicenter study of pneumonia in lung transplant recipients, 40 of 85 episodes of pneumonia (44 percent) occurred during the first 30 days following transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/10\">",
"     10",
"    </a>",
"    ]. Early post-transplant pneumonias are typically caused by hospital-acquired bacteria, including multidrug-resistant Pseudomonas aeruginosa, Enterobacteriaceae, and methicillin-resistant Staphylococcus aureus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacterial infections can be transmitted from the donor or develop in the setting of the post-transplant intensive care unit admission. It is essential to appreciate that a positive Gram stain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    culture from the donor lung neither establishes the diagnosis of pneumonia nor excludes other potential sites of infection; multiple studies have found no association between donor colonization and subsequent development of pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Although approximately 60 percent of donor lungs are colonized, only 6 to 12 percent of recipients develop active infection transmitted from the donor lungs if they receive appropriate antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. However, the detection of certain bacteria from the donor lung(s) warrants additional antibacterials beyond the usual period of perioperative prophylaxis, as discussed below. (See",
"    <a class=\"local\" href=\"#H13586165\">",
"     'Routine perioperative prophylaxis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H13586136\">",
"     'Positive donor lung cultures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Later in the time course (especially more than six months post-transplant), lung transplant recipients are also at risk for developing pneumonia from community-acquired bacterial pathogens. In addition, the risk for infection with multidrug-resistant bacteria remains elevated due to the transplant recipient's frequent exposure to health care facilities and increased use of antibacterial agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=see_link\">",
"     \"Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the usual community-acquired and hospital-acquired pathogens, lung transplant recipients are at increased risk for infection with bacteria that are non-pathogenic in the immunocompetent host, including Mycoplasma hominis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/14-17\">",
"     14-17",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/18\">",
"     18",
"    </a>",
"    ], and for fungal pneumonia, most commonly caused by Aspergillus fumigatus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with cystic fibrosis (CF) are at a significantly higher risk of pneumonia compared with other lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/8,19\">",
"     8,19",
"    </a>",
"    ], and are more likely to be colonized with multidrug-resistant Pseudomonas aeruginosa and Burkholderia cepacia. Despite a decreased bacterial burden after removal of the native lungs, patients with CF are at high risk of post-transplant infection due to the potential for contamination of the bloodstream and the thoracic cavity during transplantation. Furthermore, these patients remain at increased risk for infection post-transplant because the native upper airways and sinuses of CF patients retain the chloride channel defect and remain persistently colonized with the pathogens that were present pre-transplant, particularly Pseudomonas aeruginosa and Burkholderia cepacia. (See",
"    <a class=\"local\" href=\"#H1627022286\">",
"     'Pseudomonas aeruginosa'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1627022308\">",
"     'Burkholderia cepacia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27145?source=see_link\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=see_link\">",
"     \"Pseudomonas aeruginosa pneumonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022241\">",
"    <span class=\"h3\">",
"     Pleural space infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reaccumulation of pleural fluid after the initial post-transplant chest tube removal can occur due to hemorrhage, rejection, or infection. Pleural fluid accumulation that worsens beyond the first few days following transplantation warrants immediate investigation to exclude empyema [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/20\">",
"     20",
"    </a>",
"    ]. Empyema occurs in 3 to 5 percent of lung transplant recipients; almost all of these infections occur during the first six months after transplantation, with 40 percent occurring within the first month [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The incidence of pleural space infections does not appear to be dependent on underlying lung disease or surgical procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/21,23,24\">",
"     21,23,24",
"    </a>",
"    ]. However, case reports show an increased incidence of pleural space infections due to Burkholderia cepacia in patients with cystic fibrosis who harbor this organism pre-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/25\">",
"     25",
"    </a>",
"    ]. In a study of pleural space infections in 36 lung transplant recipients, the most common causes were fungi (in 61 percent) and bacteria (in 31 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/24\">",
"     24",
"    </a>",
"    ]. No bacterial species predominated; there were two cases each of Burkholderia cepacia, Escherichia coli, and Mycoplasma hominis, and one case each of Staphylococcus aureus, Enterococcus spp, Pseudomonas aeruginosa, Serratia marcescens, and Roseomonas spp. Listeria monocytogenes, which rarely causes pneumonia, has been reported as a cause of empyema in a lung transplant recipient [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The short-term mortality of lung transplant recipients with empyema has been estimated to approach 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022254\">",
"    <span class=\"h3\">",
"     Bloodstream infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bloodstream infections (BSIs) are an important cause of morbidity and mortality in lung transplant recipients. In a retrospective study, BSIs were identified in up to 25 percent of lung transplant recipients, with 60 percent of episodes occurring during the transplant hospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/27\">",
"     27",
"    </a>",
"    ]. Risks for BSI include the use of central venous catheters, mechanical ventilation, and cystic fibrosis. BSIs in transplant recipients reflect the pattern of bloodstream infections in immunocompetent hospitalized patients and are most frequently due to Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus spp, and Candida spp [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=see_link\">",
"     \"Epidemiology, pathogenesis, and microbiology of intravascular catheter infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=see_link\">",
"     \"Epidemiology of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20681?source=see_link\">",
"     \"Gram-negative bacillary bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=see_link\">",
"     \"Epidemiology and pathogenesis of candidemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The development of BSI is associated with increased mortality for both adult and pediatric lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. In a multivariate analysis, BSI was associated with an almost sixfold increased risk of death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/27\">",
"     27",
"    </a>",
"    ]. Blood cultures should be obtained in all lung transplant recipients presenting with pneumonia or any systemic signs or symptoms of infection following transplantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022267\">",
"    <span class=\"h3\">",
"     Skin and soft tissue infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the high degree of immunosuppression puts lung transplant recipients at risk for infection of the surgical site, this occurs infrequently. The same nosocomial pathogens that cause early post-transplant bloodstream and lung infections (eg, Pseudomonas aeruginosa, Staphylococcus aureus, Candida spp) are the most common causes of wound infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/29\">",
"     29",
"    </a>",
"    ]. Pseudomonas aeruginosa is of particular concern in patients with cystic fibrosis due to pretransplant colonization with this organism and the risk for perioperative seeding of the surgical wound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"     \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27145?source=see_link\">",
"     \"Epidemiology and pathogenesis of Pseudomonas aeruginosa infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mycoplasma hominis is a rare but reported cause of wound infection after lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022279\">",
"    <span class=\"h2\">",
"     Specific pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplant recipients are susceptible to a broad range of gram-positive and gram-negative infections. Patients with cystic fibrosis (CF) have unique risk factors for infection following transplantation. In particular, patients with CF are often colonized with methicillin-resistant Staphylococcus aureus, as well as such gram-negative bacteria as Pseudomonas aeruginosa and Burkholderia cepacia, both of which are frequently multidrug-resistant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022286\">",
"    <span class=\"h3\">",
"     Pseudomonas aeruginosa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly 50 percent of Pseudomonas isolates in lung transplant recipients are resistant to one or more antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/19\">",
"     19",
"    </a>",
"    ]. While the safety of lung transplantation in patients colonized with multidrug-resistant pathogens has been a matter of controversy since the beginning of lung transplantation, an increasing number of studies has shown acceptable survival for lung transplantation in patients colonized with multidrug-resistant gram-negative bacteria prior to transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. As an example, in one retrospective study, one year survival for cystic fibrosis (CF) patients colonized with multidrug-resistant Pseudomonas aeruginosa was greater than 80 percent and was similar to other patients with CF who were not colonized with resistant bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/30\">",
"     30",
"    </a>",
"    ]. Based on these findings, pre-transplant colonization with multidrug-resistant P. aeruginosa should not exclude patients from consideration for transplant. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022308\">",
"    <span class=\"h3\">",
"     Burkholderia cepacia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burkholderia cepacia (formerly known as Pseudomonas cepacia) is a gram-negative rod that commonly colonizes the lungs of patients with cystic fibrosis (CF), and is frequently multidrug-resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/32\">",
"     32",
"    </a>",
"    ]. B. cepacia has been classified into nine genomovars, which are phenotypically similar but genotypically distinct [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/33\">",
"     33",
"    </a>",
"    ]. B. cenocepacia (genomovar III) and B. multivorans (genomovar II) are the most common causes of B. cepacia colonization and infection in CF patients, although the prevalence of each genomovar varies by geographic region. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=see_link&amp;anchor=H902257#H902257\">",
"     \"Cystic fibrosis: Antibiotic therapy for lung disease\", section on 'Burkholderia cepacia complex'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been shown that pre-transplant B. cepacia colonization is associated with higher early post-transplant mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/25,30,34\">",
"     25,30,34",
"    </a>",
"    ]. However, subsequent studies have suggested that increased post-transplant mortality is associated only with B. cenocepacia (genomovar III), but not with B. multivorans (genomovar II) or other genomovars [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/33,35-38\">",
"     33,35-38",
"    </a>",
"    ]. In a study of 75 lung transplant recipients with CF, seven were colonized with B. cenocepacia, nine were colonized with other genomovars of B. cepacia, and 59 were not colonized with B. cepacia pre-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/33\">",
"     33",
"    </a>",
"    ]. One-year survival of patients with B. cenocepacia was 29 percent, compared with 89 percent for those with other B. cepacia genomovars, and 92 percent for those without B. cepacia. In another study that included 28 patients who were colonized with B. cenocepacia pre-transplant, one year survival was 67 percent in colonized patients versus 92 percent among non-colonized patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/25\">",
"     25",
"    </a>",
"    ]. Notably, 60 percent of deaths in the B. cepacia cohort occurred in the early post-transplant period and was characterized by progressive acute respiratory distress syndrome and sepsis (cepacia syndrome). Later complications of B. cepacia colonization include lung abscess and empyema.",
"   </p>",
"   <p>",
"    Available data support screening of all patients with CF for B. cenocepacia. Colonization with this strain is viewed as a relative contraindication to transplantation. If transplantation is attempted in patients who harbor B. cenocepacia, early aggressive antimicrobial prophylaxis should be employed in an effort to decrease early B. cepacia-related mortality. (See",
"    <a class=\"local\" href=\"#H162322\">",
"     'Positive native lung cultures'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604872\">",
"    <span class=\"h3\">",
"     Other gram-negative bacteria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to Pseudomonas aeruginosa and Burkholderia cepacia, other gram-negative bacteria species can cause pneumonia in lung transplant recipients, some of which are multidrug-resistant. Commonly encountered gram-negative species include Acinetobacter spp, Stenotrophomonas maltophilia, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, and Escherichia coli [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604897\">",
"    <span class=\"h3\">",
"     Staphylococcus aureus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus aureus, including methicillin-resistant S. aureus, is a common cause of hospital-acquired, healthcare-associated, and ventilator-associated pneumonia, as well as bacteremia and wound infections. Specific infections caused by S. aureus are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=see_link\">",
"     \"Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=see_link\">",
"     \"Epidemiology of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=see_link\">",
"     \"Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022321\">",
"    <span class=\"h3\">",
"     Streptococcus pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lung transplant recipients in the late post-transplant period (more than six months following transplantation) are susceptible to typical community-acquired pathogens such as Streptococcus pneumoniae, which is the most common cause of community-acquired pneumonia. Despite the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    for Pneumocystis prophylaxis, lung transplant recipients have a greater likelihood of developing invasive pneumococcal infection and bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, they have an increased incidence of infection with resistant S. pneumoniae, with approximately 80 percent of isolates resistant to trimethoprim-sulfamethoxazole and 60 percent with intermediate- or high-level penicillin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=see_link\">",
"     \"Pneumococcal pneumonia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) should be administered prior to transplantation, because antibody responses are impaired after transplantation due to immunosuppression. Revaccination should be performed once, five years after the initial immunization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022334\">",
"    <span class=\"h3\">",
"     Chlamydia pneumoniae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper and lower respiratory tract infections are frequently due to the obligate intracellular bacteria, Chlamydia pneumoniae. Due to the difficulty in culturing Chlamydia, diagnosis relies on serological and molecular techniques. These limitations have led to an underestimation of the frequency of Chlamydia infection in the early post-transplant period.",
"   </p>",
"   <p>",
"    One study employed polymerase chain reaction (PCR) for Chlamydia on bronchoalveolar lavage fluid in lung transplant recipients during the early post-transplant period. A positive PCR for Chlamydia was identified in 25 percent of patients within the first month post-transplant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/40\">",
"     40",
"    </a>",
"    ]. The identification of Chlamydia spp was associated with adverse outcomes, including allograft rejection, airway complications, and increased mortality. In addition, possible donor transmission of Chlamydia was observed in three patients. Until newer diagnostic techniques are widely available, clinicians must have a high index of suspicion for this underappreciated pathogen in lung transplant recipients.",
"   </p>",
"   <p>",
"    In addition to causing upper and lower respiratory tract infections, C. pneumoniae has been implicated as a possible cause of bronchiolitis obliterans syndrome (BOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/41\">",
"     41",
"    </a>",
"    ]. In a study that assessed the impact of C. pneumoniae on the development of BOS in 76 lung transplant recipients, the presence of elevated donor antibodies against Chlamydia was associated with earlier and more frequent development of BOS. On the other hand, the presence of antibodies in the recipient prior to transplant appeared to be protective from BOS. Although the reason for this association is not well understood, it is possible that immunosuppression leads to reactivation of latent Chlamydia infection in the allograft and inflammation contributes to chronic allograft rejection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=see_link\">",
"     \"Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022347\">",
"    <span class=\"h3\">",
"     Nocardia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections caused by Nocardia species are rare. The majority of cases occur in immunocompromised patients, including solid organ transplant recipients. Approximately 1.9 to 3.5 percent of lung transplant recipients develop nocardiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/42-44\">",
"     42-44",
"    </a>",
"    ], with a mean onset of 14.3 months after transplantation (range 1.5 to 39 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/42\">",
"     42",
"    </a>",
"    ]. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    has activity against Nocardia species, cases of nocardiosis have occurred in patients receiving thrice weekly trimethoprim-sulfamethoxazole prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/42,44\">",
"     42,44",
"    </a>",
"    ]. Nocardia species most commonly cause pneumonia in lung transplant recipients, typically with a subacute presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nocardiosis should be considered in lung transplant recipients with pneumonia, particularly if it does not respond to empiric therapy. Special staining (modified acid fast bacillus staining) and cultures should be requested when infection with Nocardia spp is suspected (",
"    <a class=\"graphic graphic_table graphicRef70685 \" href=\"UTD.htm?28/8/28813\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=see_link&amp;anchor=H11#H11\">",
"     \"Microbiology, epidemiology, and pathogenesis of nocardiosis\", section on 'Organ transplant recipients'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=see_link\">",
"     \"Clinical manifestations and diagnosis of nocardiosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=see_link\">",
"     \"Treatment of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022359\">",
"    <span class=\"h3\">",
"     Clostridium difficile",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clostridium difficile infection is a common problem in lung transplant recipients, with an estimated incidence of 7 to 31 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. C. difficile infection occurs most frequently in the early period following transplantation and in those requiring prolonged hospitalization. The intense immunosuppression and frequent exposure to antimicrobial agents that occur shortly after transplantation likely contribute to the increased risk for C. difficile infection during this period [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=see_link\">",
"     \"Clostridium difficile in adults: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022723\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Empiric therapy should be based on prior culture data, when available, and antibiotics adjusted as needed by repeat cultures when possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604798\">",
"    <span class=\"h2\">",
"     Pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having bacterial pneumonia should be treated empirically according to the type of pneumonia (eg, community-acquired, hospital-acquired), risk factors for multidrug-resistant bacteria, and severity of illness. An aggressive diagnostic evaluation should be undertaken concurrently, and clinicians should have a low threshold to perform bronchoscopy. (See",
"    <a class=\"local\" href=\"#H1627022190\">",
"     'Diagnostic approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If patients have received an antibiotic recently, empiric therapy should generally be with a drug from a different class since earlier treatment may have selected pathogens resistant to the initial class. Patients with cystic fibrosis who are known to be colonized with multidrug-resistant bacteria such as Pseudomonas aeruginosa or Burkholderia cepacia should be treated according to prior microbiologic data. Empiric antibiotic therapy should be tailored after 48 to 72 hours based on culture data from sputum, bronchoalveolar lavage fluid,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood cultures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604664\">",
"    <span class=\"h3\">",
"     Hospital-acquired, ventilator-associated, and healthcare-associated pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For lung transplant recipients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), or healthcare-associated pneumonia (HCAP) for whom no prior culture data are available, the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) recommend initial therapy with three antibiotics including two agents for gram-negative bacteria, as well as coverage for methicillin-resistant Staphylococcus aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/48\">",
"     48",
"    </a>",
"    ]. Such a regimen is intended to cover multidrug-resistant bacteria, including Pseudomonas aeruginosa, given the increased risk for such pathogens in immunocompromised patients.",
"   </p>",
"   <p>",
"    Specific regimens for HAP, VAP, and HCAP are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H604684\">",
"    <span class=\"h3\">",
"     Community-acquired pneumonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;For lung transplant recipients with community-acquired pneumonia (CAP), it is important to include coverage for Streptococcus pneumoniae, which is the most common cause of CAP, in addition to atypical pathogens such as Mycoplasma, Chlamydia, and Legionella, with a respiratory fluoroquinolone or macrolide. For those with risk factors for methicillin-resistant Staphylococcus aureus, Pseudomonas aeruginosa,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other multidrug-resistant bacteria, the empiric regimen should also have activity against these pathogens. Specific regimens for patients with CAP are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"     \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13586014\">",
"    <span class=\"h3\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no high quality data to guide the duration of antibiotic therapy for bacterial pneumonia in lung transplant recipients. Short-course antibiotic therapy for eight days has only been validated in the immunocompetent host with ventilator-associated pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/49\">",
"     49",
"    </a>",
"    ]. In most cases, two weeks of antibiotics is an appropriate duration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link&amp;anchor=H14#H14\">",
"     \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\", section on 'Duration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of community-acquired pneumonia in adults who require hospitalization\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13586003\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of pleural space infections in lung transplant recipients requires drainage as well as a prolonged course of antimicrobial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some skin and soft tissue infections require surgical debridement as well as prolonged antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=see_link\">",
"     \"Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=see_link\">",
"     \"Necrotizing soft tissue infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=see_link\">",
"     \"Pseudomonas aeruginosa skin, soft tissue, and bone infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The general approach to bloodstream infections is similar as the approach in non-transplant patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=see_link\">",
"     \"Parapneumonic effusion and empyema in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=see_link\">",
"     \"Treatment of intravascular catheter-related infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=see_link\">",
"     \"Treatment of Staphylococcus aureus bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20681?source=see_link\">",
"     \"Gram-negative bacillary bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=see_link\">",
"     \"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42551?source=see_link\">",
"     \"Group A streptococcal (Streptococcus pyogenes) bacteremia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=see_link\">",
"     \"Treatment of enterococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022736\">",
"    <span class=\"h1\">",
"     PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no randomized trials that prove the value of early post-transplant systemic antimicrobial prophylaxis, it is typically administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022748\">",
"    <span class=\"h2\">",
"     Systemic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic prophylaxis regimens should be chosen to broadly cover the common gram-positive and gram-negative pathogens associated with nosocomial infection at a particular institution, and should also be tailored to cover likely pathogens in a given patient based on prior microbiology data and risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13586165\">",
"    <span class=\"h3\">",
"     Routine perioperative prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;We usually use a regimen of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (1 g IV with induction of anesthesia, then 1 g every 12 hours) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    (2 g IV with induction of anesthesia, then 1 g every eight hours) (",
"    <a class=\"graphic graphic_table graphicRef78763 \" href=\"UTD.htm?15/28/15820\">",
"     table 3",
"    </a>",
"    ). Such a regimen is designed to cover methicillin-resistant Staphylococcus aureus as well as Pseudomonas aeruginosa and other gram-negative bacteria, although the specific regimen chosen depends upon local resistance patterns and the patient's microbiologic data. For patients undergoing lung transplantation for cystic fibrosis, in particular, the regimen should be tailored to cover the susceptibility patterns of the known pre-transplant pathogens. (See",
"    <a class=\"local\" href=\"#H162322\">",
"     'Positive native lung cultures'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    For patients with an uncomplicated course following transplantation, we continue systemic antibacterial prophylaxis for 7 to 10 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4589847\">",
"    <span class=\"h3\">",
"     Trimethoprim-sulfamethoxazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     Trimethoprim-sulfamethoxazole",
"    </a>",
"    (TMP-SMX), which is the agent of choice for Pneumocystis jirovecii (formerly P. carinii) pneumonia prophylaxis, has the added benefit of having activity against various other pathogens such as Streptococcus pneumoniae, Listeria monocytogenes, and Toxoplasma gondii. It also has activity against Nocardia spp, although cases of nocardiosis have occurred in solid organ transplant recipients receiving TMP-SMX prophylaxis. TMP-SMX should be started within one week postoperatively. The usual dosing is one double-strength tablet daily or three times per week, continued indefinitely (",
"    <a class=\"graphic graphic_table graphicRef78763 \" href=\"UTD.htm?15/28/15820\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link&amp;anchor=H26#H26\">",
"     \"Fungal infections following lung transplantation\", section on 'Pneumocystis pneumonia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13586129\">",
"    <span class=\"h2\">",
"     Positive lung cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;When cultures are positive from either the donor lung at the time of transplantation or from the native lungs, either from the pre-transplant period or from the time of transplantation, treatment is advisable to prevent the development of anastomotic complications, pneumonia, and thoracic space infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13586136\">",
"    <span class=\"h3\">",
"     Positive donor lung cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial washings are routinely obtained from the donor lungs for Gram stain and culture during transplantation. When such cultures are positive, the lung transplant recipient is usually treated with antimicrobial agents that target the isolated species. Lung transplant recipients should generally be treated for two weeks with directed antibacterial therapy against Staphylococcus aureus or gram-negative bacilli when one of these pathogens is isolated from the donor lung(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/50\">",
"     50",
"    </a>",
"    ]. A shorter course is reasonable when less virulent bacteria are detected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H162322\">",
"    <span class=\"h3\">",
"     Positive native lung cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients colonized pretransplant with multidrug-resistant bacteria, such as Pseudomonas aeruginosa or Burkholderia cepacia, aggressive antimicrobial prophylaxis with multiple agents from different classes is administered during the post-transplant period. The specific regimen depends upon the resistance patterns of the individual patient&rsquo;s isolates. (See",
"    <a class=\"local\" href=\"#H1627022308\">",
"     'Burkholderia cepacia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H1627022286\">",
"     'Pseudomonas aeruginosa'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As discussed above, Burkholderia cenocepacia is associated with significantly worse post-transplant survival compared with CF patients not colonized with this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/33-37\">",
"     33-37",
"    </a>",
"    ]. For this reason, colonization with B. cenocepacia is considered a relative contraindication to transplantation, and is generally performed only at a limited number of transplant centers with experience managing such patients. (See",
"    <a class=\"local\" href=\"#H1627022308\">",
"     'Burkholderia cepacia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022761\">",
"    <span class=\"h2\">",
"     Adjunctive strategies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adjunctive approaches to systemic antibiotics include inhaled antimicrobial agents and removal of potential infectious reservoirs. While the role of inhaled antibiotics such as aminoglycosides has not been rigorously studied, the potential to decrease colonization of the allograft with minimal systemic toxicity may be an appealing strategy in patients at high risk for multidrug-resistant organisms, such as Pseudomonas and Burkholderia spp.",
"   </p>",
"   <p>",
"    The use of inhaled aminoglycosides in addition to systemic therapy is often used for patients with cystic fibrosis or other septic lung disease in which patients are known to be colonized with gram-negative bacteria prior to transplant. Inhaled aminoglycosides are also frequently used post-transplant for multidrug-resistant gram-negative infections in any host.",
"   </p>",
"   <p>",
"    Other prophylactic measures include clearance of the bacterial reservoir in the sinuses of patients with cystic fibrosis or other ciliary function defects. The sinuses serve as a major reservoir for bacterial pathogens in patients with cystic fibrosis. There are conflicting data regarding whether pre-transplant sinus surgery decreases the incidence of bacterial colonization of the lungs, tracheobronchitis, or pneumonia after lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The American Society of Transplantation therefore does not recommend routine pre-transplant surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/30/12778/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Central venous catheters should be removed as early as possible post-transplant to limit the risk of bloodstream infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022774\">",
"    <span class=\"h1\">",
"     VACCINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of infection is of paramount importance to the lung transplant recipient. Infection in these patients results in excessive morbidity and mortality, and antimicrobial therapy is often less effective than in the immunocompetent host. Although immunization appears to be an obvious way to prevent infection, many immunocompromised patients are unable to mount protective immune responses. Furthermore, immunization with live virus vaccines may result in unchecked proliferation of attenuated vaccine strains and is therefore generally avoided in solid organ transplant recipients.",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) should be administered prior to transplantation, and revaccination should be performed once, five years after the initial immunization. Detailed recommendations regarding PPSV23 and other vaccines for individuals who are awaiting or have undergone solid organ transplantation are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=see_link\">",
"     \"Immunizations in solid organ transplant candidates and recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1627022787\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung transplant recipients are at increased risk for infectious complications due to the high level of immunosuppression required to prevent rejection, adverse effects of transplantation on local pulmonary host defenses (eg, reduced mucociliary clearance), and constant environmental contact allowing pathogens direct access into the allograft. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pneumonia is the most common type of infection in lung transplant recipients, although bloodstream, pleural space, and wound infections are also common. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk of infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with cystic fibrosis (CF) have unique risk factors for infection following transplantation. In particular, patients with CF are often colonized with such gram-negative bacteria as Pseudomonas aeruginosa and Burkholderia cepacia, both of which are frequently multidrug-resistant. (See",
"      <a class=\"local\" href=\"#H1627022279\">",
"       'Specific pathogens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients suspected of having bacterial pneumonia should be treated empirically according to the type of pneumonia (eg, community-acquired, hospital-acquired), risk factors for multidrug-resistant bacteria, and severity of illness. We typically treat lung transplant recipients with community-acquired, hospital-acquired, ventilator-associated, or healthcare-associated pneumonia according to the regimens outlined in the American Thoracic",
"      <span class=\"nowrap\">",
"       Society/Infectious",
"      </span>",
"      Diseases Society of America guidelines. The treatment duration in lung transplant recipients with uncomplicated bacterial pneumonia should generally be two weeks. (See",
"      <a class=\"local\" href=\"#H604798\">",
"       'Pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend perioperative antibacterial prophylaxis for all lung transplant recipients (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). For routine perioperative antibacterial prophylaxis in lung transplant recipients, we favor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/0/17415?source=see_link\">",
"       ceftazidime",
"      </a>",
"      , although the choice of regimen should be based upon local resistance patterns and the patient&rsquo;s microbiologic data. For patients with an uncomplicated course following transplantation, we continue systemic antibacterial prophylaxis for 7 to 10 days. (See",
"      <a class=\"local\" href=\"#H1627022736\">",
"       'Prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When Staphylococcus aureus or gram-negative bacilli are isolated from the donor lung(s), we recommend that lung transplant recipients be treated with directed antibacterial therapy against the species isolated (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We favor a two week course of antibiotics for these bacteria. (See",
"      <a class=\"local\" href=\"#H13586136\">",
"       'Positive donor lung cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      for Pneumocystis prophylaxis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ); in addition to anti-Pneumocystis activity, trimethoprim-sulfamethoxazole also has activity against Streptococcus pneumoniae, Listeria, Nocardia, and Toxoplasma species. The usual dosing is one double-strength tablet daily or three times per week, continued indefinitely. (See",
"      <a class=\"local\" href=\"#H1627022736\">",
"       'Prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients with cystic fibrosis should be screened for B. cenocepacia prior to transplantation. Colonization with this strain is viewed as a relative contraindication to transplantation. (See",
"      <a class=\"local\" href=\"#H1627022308\">",
"       'Burkholderia cepacia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H162322\">",
"       'Positive native lung cultures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients colonized pretransplant with multidrug-resistant bacteria, aggressive antimicrobial prophylaxis with multiple agents from different classes is administered during the post-transplant period. (See",
"      <a class=\"local\" href=\"#H162322\">",
"       'Positive native lung cultures'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Scientific Registry of Transplant Recipients. One year unadjusted patient survival by organ, 2007. file://www.ustransplant.org/csr/current/Centers/Default.aspx (Accessed on July 21, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/2\">",
"      Christie JD, Edwards LB, Aurora P, et al. The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009. J Heart Lung Transplant 2009; 28:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/3\">",
"      Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. Proc Am Thorac Soc 2009; 6:94.",
"     </a>",
"    </li>",
"    <li>",
"     Gavalda, J, Roman, et al. Risks and epidemiology of infections after lung or heart-lung transplantation. In: Transplant Infections, 3rd ed, Bowden, RA, Ljungman, P, Snydman, DR (Eds), Lippincott Williams and Wilkins, 2010. p.114.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/5\">",
"      Husain S, Singh N. Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology. Semin Respir Infect 2002; 17:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/6\">",
"      Chan CC, Abi-Saleh WJ, Arroliga AC, et al. Diagnostic yield and therapeutic impact of flexible bronchoscopy in lung transplant recipients. J Heart Lung Transplant 1996; 15:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/7\">",
"      Zaas AK, Alexander BD. New developments in the diagnosis and treatment of infections in lung transplant recipients. Respir Care Clin N Am 2004; 10:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/8\">",
"      Nunley DR, Grgurich W, Iacono AT, et al. Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients. Chest 1998; 113:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/9\">",
"      Ruiz I, Gavald&agrave; J, Monforte V, et al. Donor-to-host transmission of bacterial and fungal infections in lung transplantation. Am J Transplant 2006; 6:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/10\">",
"      Aguilar-Guisado M, Givald&aacute; J, Ussetti P, et al. Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study. Am J Transplant 2007; 7:1989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/11\">",
"      Weill D, Dey GC, Hicks RA, et al. A positive donor gram stain does not predict outcome following lung transplantation. J Heart Lung Transplant 2002; 21:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/12\">",
"      Freeman RB, Giatras I, Falagas ME, et al. Outcome of transplantation of organs procured from bacteremic donors. Transplantation 1999; 68:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/13\">",
"      Lumbreras C, Sanz F, Gonz&aacute;lez A, et al. Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients. Clin Infect Dis 2001; 33:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/14\">",
"      Hopkins P. A cluster of mycoplasma hominis infection in heart-lung transplantation. J Heart Lung Transplant 2001; 20:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/15\">",
"      Hopkins PM, Winlaw DS, Chhajed PN, et al. Mycoplasma hominis infection in heart and lung transplantation. J Heart Lung Transplant 2002; 21:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/16\">",
"      Lyon GM, Alspaugh JA, Meredith FT, et al. Mycoplasma hominis pneumonia complicating bilateral lung transplantation: case report and review of the literature. Chest 1997; 112:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/17\">",
"      Mossad SB, Rehm SJ, Tomford JW, et al. Sternotomy infection with Mycoplasma hominis: a cause of \"culture negative\" wound infection. J Cardiovasc Surg (Torino) 1996; 37:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/18\">",
"      Carretto E, Barbarini D, Marzani FC, et al. Catheter-related bacteremia due to Lactobacillus rhamnosus in a single-lung transplant recipient. Scand J Infect Dis 2001; 33:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/19\">",
"      Kanj SS, Tapson V, Davis RD, et al. Infections in patients with cystic fibrosis following lung transplantation. Chest 1997; 112:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/20\">",
"      Judson MA, Handy JR, Sahn SA. Pleural effusions following lung transplantation. Time course, characteristics, and clinical implications. Chest 1996; 109:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/21\">",
"      Nunley DR, Grgurich WF, Keenan RJ, Dauber JH. Empyema complicating successful lung transplantation. Chest 1999; 115:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/22\">",
"      Herridge MS, de Hoyos AL, Chaparro C, et al. Pleural complications in lung transplant recipients. J Thorac Cardiovasc Surg 1995; 110:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/23\">",
"      Backhus LM, Sievers EM, Schenkel FA, et al. Pleural space problems after living lobar transplantation. J Heart Lung Transplant 2005; 24:2086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/24\">",
"      Wahidi MM, Willner DA, Snyder LD, et al. Diagnosis and outcome of early pleural space infection following lung transplantation. Chest 2009; 135:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/25\">",
"      Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001; 163:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/26\">",
"      Janssens W, Van Raemdonck D, Dupont L, Verleden GM. Listeria pleuritis 1 week after lung transplantation. J Heart Lung Transplant 2006; 25:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/27\">",
"      Palmer SM, Alexander BD, Sanders LL, et al. Significance of blood stream infection after lung transplantation: analysis in 176 consecutive patients. Transplantation 2000; 69:2360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/28\">",
"      Danziger-Isakov LA, Sweet S, Delamorena M, et al. Epidemiology of bloodstream infections in the first year after pediatric lung transplantation. Pediatr Infect Dis J 2005; 24:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/29\">",
"      Routledge T, Saeb-Parsy K, Murphy F, Ritchie AJ. The use of vacuum-assisted closure in the treatment of post-transplant wound infections: a case series. J Heart Lung Transplant 2005; 24:1444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/30\">",
"      Aris RM, Gilligan PH, Neuringer IP, et al. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. Am J Respir Crit Care Med 1997; 155:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/31\">",
"      Dobbin C, Maley M, Harkness J, et al. The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. J Hosp Infect 2004; 56:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/32\">",
"      van Delden C, Blumberg EA, AST Infectious Diseases Community of Practice. Multidrug resistant gram-negative bacteria in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/33\">",
"      Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008; 8:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/34\">",
"      Snell GI, de Hoyos A, Krajden M, et al. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993; 103:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/35\">",
"      Boussaud V, Guillemain R, Grenet D, et al. Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: results from two French centres. Thorax 2008; 63:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/36\">",
"      Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001; 164:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/37\">",
"      De Soyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001; 358:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/38\">",
"      Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001; 33:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/39\">",
"      de Bruyn G, Whelan TP, Mulligan MS, et al. Invasive pneumococcal infections in adult lung transplant recipients. Am J Transplant 2004; 4:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/40\">",
"      Glanville AR, Gencay M, Tamm M, et al. Chlamydia pneumoniae infection after lung transplantation. J Heart Lung Transplant 2005; 24:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/41\">",
"      Kotsimbos TC, Snell GI, Levvey B, et al. Chlamydia pneumoniae serology in donors and recipients and the risk of bronchiolitis obliterans syndrome after lung transplantation. Transplantation 2005; 79:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/42\">",
"      Poonyagariyagorn HK, Gershman A, Avery R, et al. Challenges in the diagnosis and management of Nocardia infections in lung transplant recipients. Transpl Infect Dis 2008; 10:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/43\">",
"      Husain S, McCurry K, Dauber J, et al. Nocardia infection in lung transplant recipients. J Heart Lung Transplant 2002; 21:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/44\">",
"      Peleg AY, Husain S, Qureshi ZA, et al. Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case-control study. Clin Infect Dis 2007; 44:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/45\">",
"      Clark NM, AST Infectious Diseases Community of Practice. Nocardia in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/46\">",
"      Dubberke ER, Riddle DJ, AST Infectious Diseases Community of Practice. Clostridium difficile in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/47\">",
"      Riddle DJ, Dubberke ER. Clostridium difficile infection in solid organ transplant recipients. Curr Opin Organ Transplant 2008; 13:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/48\">",
"      American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/49\">",
"      Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/50\">",
"      Fischer SA, Avery RK, AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009; 9 Suppl 4:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/51\">",
"      Holzmann D, Speich R, Kaufmann T, et al. Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience. Transplantation 2004; 77:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/30/12778/abstract/52\">",
"      Leung MK, Rachakonda L, Weill D, Hwang PH. Effects of sinus surgery on lung transplantation outcomes in cystic fibrosis. Am J Rhinol 2008; 22:192.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1395 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-201.65.114.212-1237D62C13-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12778=[""].join("\n");
var outline_f12_30_12778=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1627022787\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RISK OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022150\">",
"      TIMELINE OF INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EVALUATION FOR INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022190\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022209\">",
"      BACTERIAL INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022221\">",
"      Sites of infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022228\">",
"      - Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022241\">",
"      - Pleural space infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022254\">",
"      - Bloodstream infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022267\">",
"      - Skin and soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022279\">",
"      Specific pathogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022286\">",
"      - Pseudomonas aeruginosa",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022308\">",
"      - Burkholderia cepacia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H604872\">",
"      - Other gram-negative bacteria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H604897\">",
"      - Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022321\">",
"      - Streptococcus pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022334\">",
"      - Chlamydia pneumoniae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022347\">",
"      - Nocardia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022359\">",
"      - Clostridium difficile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022723\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H604798\">",
"      Pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H604664\">",
"      - Hospital-acquired, ventilator-associated, and healthcare-associated pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H604684\">",
"      - Community-acquired pneumonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13586014\">",
"      - Duration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13586003\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022736\">",
"      PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022748\">",
"      Systemic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13586165\">",
"      - Routine perioperative prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4589847\">",
"      - Trimethoprim-sulfamethoxazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13586129\">",
"      Positive lung cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13586136\">",
"      - Positive donor lung cultures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H162322\">",
"      - Positive native lung cultures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022761\">",
"      Adjunctive strategies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022774\">",
"      VACCINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1627022787\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1395\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1395|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/59/18365\" title=\"table 1\">",
"      Infection risk factors in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/8/28813\" title=\"table 2\">",
"      BAL studies in immunocompromised hosts with pneumonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/28/15820\" title=\"table 3\">",
"      Antimicrobial prophylaxis lung transplant",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/25/18841?source=related_link\">",
"      Chronic lung transplant rejection: Bronchiolitis obliterans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/6/16489?source=related_link\">",
"      Clinical manifestations and diagnosis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/39/29305?source=related_link\">",
"      Clostridium difficile in adults: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/22/41322?source=related_link\">",
"      Cystic fibrosis: Antibiotic therapy for lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/32/27145?source=related_link\">",
"      Epidemiology and pathogenesis of Pseudomonas aeruginosa infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37638?source=related_link\">",
"      Epidemiology and pathogenesis of candidemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/1/10263?source=related_link\">",
"      Epidemiology of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/53/8026?source=related_link\">",
"      Epidemiology of methicillin-resistant Staphylococcus aureus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/49/31514?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37464?source=related_link\">",
"      Epidemiology, pathogenesis, and microbiology of intravascular catheter infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12183?source=related_link\">",
"      Epidemiology, pathogenesis, microbiology, and diagnosis of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3994?source=related_link\">",
"      Evaluation and treatment of acute lung transplant rejection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/12/20681?source=related_link\">",
"      Gram-negative bacillary bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42551?source=related_link\">",
"      Group A streptococcal (Streptococcus pyogenes) bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/48/23306?source=related_link\">",
"      Immunizations in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=related_link\">",
"      Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23991?source=related_link\">",
"      Microbiology, epidemiology, and pathogenesis of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/22/362?source=related_link\">",
"      Necrotizing soft tissue infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28089?source=related_link\">",
"      Parapneumonic effusion and empyema in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/4/13386?source=related_link\">",
"      Pneumococcal pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7270?source=related_link\">",
"      Pneumonia caused by Chlamydophila (Chlamydia) pneumoniae in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/48/31494?source=related_link\">",
"      Pseudomonas aeruginosa pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/8/43142?source=related_link\">",
"      Pseudomonas aeruginosa skin, soft tissue, and bone infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/43/24249?source=related_link\">",
"      Treatment of Staphylococcus aureus bacteremia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7498?source=related_link\">",
"      Treatment of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/48/21258?source=related_link\">",
"      Treatment of invasive methicillin-resistant Staphylococcus aureus infections in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=related_link\">",
"      Treatment of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/7/4216?source=related_link\">",
"      Treatment of skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_30_12779="Relative contraindications to IUD insertion";
var content_f12_30_12779=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative contraindications or warnings for IUD insertion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        For either type of IUD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk factors for STDs (non-monogamous relationship, history of STDs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of a previous IUD problem (perforation, significant pain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unresolved abnormal uterine bleeding",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Past history of severe vasovagal reactivity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        For the Cu T 380A IUD only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current anemia or a history of menorrhagia-associated anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        For the LNg 20 IUD only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of progestin intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Patient does not accept risk that she will develop amenorrhea or hypomenorrhea",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12779=[""].join("\n");
var outline_f12_30_12779=null;
var title_f12_30_12780="High fiber diet guidelines C";
var content_f12_30_12780=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    High fiber diet guidelines (continued)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Sample menu (for a 7- to 10-year old)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Breakfast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 cup instant oatmeal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 slice whole-grain toast",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 teaspoon margarine or butter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 medium banana",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8 ounces skim milk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Lunch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Turkey sandwich on whole grain bread",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 teaspoon mustard",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 ounce whole grain chips",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 medium apple",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8 baby carrots",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bottled water",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Snack 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4 fig bar cookies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8 ounces skim milk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Dinner",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3 ounces pork tenderloin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1/2 cup mashed sweet potatoes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1/2 cup green beans",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1 small whole grain roll",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2 teaspoons margarine or butter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        8 ounces skim milk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Snack 2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1/2 cup vanilla bean ice-cream",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12780=[""].join("\n");
var outline_f12_30_12780=null;
var title_f12_30_12781="DBA versus TEC";
var content_f12_30_12781=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F76264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F76264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of acquired pure red cell aplasia in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Diamond-Blackfan anemia",
"       </td>",
"       <td class=\"subtitle1\">",
"        Transient erythroblastopenia of childhood",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Age at diagnosis",
"        </strong>",
"       </td>",
"       <td>",
"        90 percent &lt;1 year",
"       </td>",
"       <td>",
"        80 percent from one to four years",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Male:Female",
"        </strong>",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"       <td>",
"        1.2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Etiology",
"        </strong>",
"       </td>",
"       <td>",
"        Constitutional",
"       </td>",
"       <td>",
"        Acquired",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Antecedent history",
"        </strong>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Viral illness",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Body height",
"        </strong>",
"       </td>",
"       <td>",
"        50 percent below standard",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Congenital anomalies",
"        </strong>",
"       </td>",
"       <td>",
"        35 percent have one or more anomaly",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Laboratory values",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin",
"       </td>",
"       <td>",
"        2 to 6 g/dL at diagnosis",
"       </td>",
"       <td>",
"        3 to 9 g/dL at diagnosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White cell count",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"       <td>",
"        Normal to decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Platelet count",
"       </td>",
"       <td>",
"        Usually normal (80 percent of patients have platelets &gt;400,000/microL)",
"       </td>",
"       <td>",
"        Normal to elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        MCV increased:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        At diagnosis",
"       </td>",
"       <td>",
"        Yes, 30 percent",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        During recovery",
"       </td>",
"       <td>",
"        Yes, 100 percent",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        During remission",
"       </td>",
"       <td>",
"        Yes, 100 percent",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\" colspan=\"3\">",
"        Hemoglobin F increased:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        At diagnosis",
"       </td>",
"       <td>",
"        Yes, 100 percent",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        During recovery",
"       </td>",
"       <td>",
"        Yes, 100 percent",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        During remission",
"       </td>",
"       <td>",
"        Yes, 85 percent",
"       </td>",
"       <td>",
"        No",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        eADA activity",
"       </td>",
"       <td>",
"        Elevated",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        i RBC antigen",
"       </td>",
"       <td>",
"        Present",
"       </td>",
"       <td>",
"        Absent",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Course",
"        </strong>",
"       </td>",
"       <td>",
"        Prolonged transfusion support or steroid therapy",
"       </td>",
"       <td>",
"        Spontaneous recovery within weeks to months",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MCV: mean corpuscular volume; eADA: erythrocyte adenosine deaminase; i RBC antigen: red blood cell i antigen.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Alter BP, Young NS. The Bone Marrow Failure Syndromes. In: Nathan and Oski's Hematology of Infancy and Childhood, Nathan DG, Orkin SH (Eds), WB Saunders, 1998, p.237.",
"       </li>",
"       <li>",
"        Oski FA, Pediatr Rev 1982; 4:25.",
"       </li>",
"       <li>",
"        Gerrits GP, van Oostrom CG, de Vaan GA, Bakkeren JA, Eur J Pediatr 1984; 142:266.",
"       </li>",
"       <li>",
"        Vlachos A, et al. Diagnosing and treating Diamond Blackfan anemia: results of an international clinical consensus conference. Br J Hematol 2008; 142:859.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12781=[""].join("\n");
var outline_f12_30_12781=null;
var title_f12_30_12782="Tuberculous tenosynovitis";
var content_f12_30_12782=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F71084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F71084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuberculous tenosynovitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 182px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cool, only slightly tender swelling of a tendon sheath is suspicious for tuberculous tenosynovitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12782=[""].join("\n");
var outline_f12_30_12782=null;
var title_f12_30_12783="Alk phos range child";
var content_f12_30_12783=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Reference range for serum alkaline phosphatase activity in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 382px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal ranges for serum alkaline phosphatase activity for boys (blue) and girls (red).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: NIH Clincal reference laboratory, available at: www.cc.nih.gov/ccc/pedweb/pedsstaff/pedlab.html",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_30_12783=[""].join("\n");
var outline_f12_30_12783=null;
